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ABSTRACT 
Mugdha Gokhale: Cardiovascular Effects Of Incretin-Based Antihyperglycemic Drugs Relative 
To Treatment Alternatives In Older Adults 
(Under the direction of Til Stürmer) 
Randomized placebo-controlled trials have examined the cardiovascular effects of 
dipeptidyl peptidase-4 inhibitors (DPP-4i), but limited data exist on the comparative incidence 
relative to therapeutic alternatives, including sulfonylureas (SU) and thiazolidinediones (TZD). 
In this study we therefore examined the comparative incidence of cardiovascular events with 
DPP-4i compared with relevant comparators using a new-user design. In recent years the use of 
SU was constant but DPP-4i use increased with a corresponding decrease in TZD use. Using 
hospitalization for heart failure (HF) as a positive control outcome we explored the use of 
calendar time as an instrumental variable (IV) and compared this approach to an active 
comparator new-user study comparing DPP-4i versus TZD. 
Using 2007-2013 US Medicare claims data, we identified two new user cohort pairs – 
DPP-4i versus SU and DPP-4i versus TZD. Since TZDs are contraindicated in patients with HF, 
we further excluded patients with diagnoses of HF or related conditions for the DPP-4i versus 
TZD analyses. Using propensity score-weighted survival analysis methods accounting for 
competing risk by death, we estimated hazard ratios (HR), risk differences (RD) and 95% 
confidence intervals (CI) for myocardial infarction (MI), stroke, HF hospitalization, and a 
composite outcome (MI, stroke, or all-cause mortality). For the IV analyses, we examined the IV 
strength and estimated RD for HF using Kaplan-Meier curves.
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The magnitude of RD per 100 patients for MI, stroke and HF hospitalization was <1 at 
one year after initiation with DPP-4i versus SU or TZD. The IV analysis compared patients 
initiating treatment during October 2010 to December 2013 versus January 2008 to May 2010 
resulting in IV strength 40%. The 1- and 2-year RD of HF using the IV approach (scaled by IV-
strength) and propensity score weighting were between 0 and -1 per 100 patients.  
Our well-controlled population based study suggests no increased short-term CV risk 
with DPP-4i relative to comparators. Both IV and propensity score-weighted approaches indicate 
lesser risk of HF hospitalizations among DPP-4i vs TZD initiators. The use of calendar time as 
an IV in settings where real-world market dynamics lead to profound changes in treatments is 
worth consideration.   
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CHAPTER 1. STATEMENT OF SPECIFIC AIMS 
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people 
with diabetes and therefore managing cardiovascular (CV) risk is important in diabetes care. 1 
Three randomized trials (SAVOR-TIMI 53 for saxagliptin, EXAMINE for alogliptin and 
TECOS for sitagliptin) examined the CV effects of adding dipeptidyl peptidase 4 inhibitor (DPP-
4i) drugs versus placebo to existing therapy but found no difference in the risk of myocardial 
infarction (MI), stroke and CV death with DPP-4i compared to placebo.2-4   SAVOR-TIMI 
however, reported increased rate of heart failure with saxagliptin compared to placebo and there 
is increased interest in evaluating this further.2, 5, 6 The evidence from observational studies 
examining the risk of heart failure with DPP-4i is mixed.7-12  To date, there are no epidemiologic 
studies exploring the comparative cardiovascular effects of DPP-4i in an older U.S. population 
with a high prevalence of comorbidities and long duration of diabetes, both of which could affect 
the effects of DPP-4i on CVD risk. Moreover the randomized trials recruited high risk 
populations, largely patients with preexisting CVD. Therefore it would be of interest to study the 
comparative incidence of cardiovascular events among initiators of DPP-4i compared to other 
second-line antihyperglycemic drugs (sulfonylureas and thiazolidinediones) in a real world 
population. 
A recent study13  examining the market trends of antihyperglycemic drugs reported that 
newly approved drugs, particularly the DPP-4i class quickly gained significant market share and 
was the most commonly prescribed new drug class by 2012.  On the other hand, the use of TZD 
decreased by 2012 potentially due to the safety concerns associated with this class in the last
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decade. DPP-4i and TZD are generally used as second-line antihyperglycemic drugs, with 
intermediate (DPP-4i) to high (TZD) efficacy, low risk of hypoglycemia14 and comparable costs 
before the generic form of pioglitazone was introduced in August 2012.15 The DPP-4i and TZD 
drugs are therefore expected to be in therapeutic equipoise in a population excluding anyone with 
clear contraindications. The increase in the use of DPP-4i with a simultaneous decrease in TZD 
use over a short period of time also provides an opportunity to use calendar time as an 
instrumental variable (IV) as suggested previously in other settings.16 
The specific aims of this project are: 
Aim 1: To compare the incidence of non-fatal MI, non-fatal stroke, all-cause mortality and 
hospitalization for heart failure among initiators of DPP-4i versus SU and TZD using Medicare 
claims data 2007 – 2013. 
Hypothesis: We hypothesized that DPP-4i would not be associated with an increased risk 
of cardiovascular outcomes relative to comparators. 
Rationale: Clinical studies have signaled potential benefit on cardiovascular risk factors 
with DPP-4i drugs. Recently completed randomized placebo controlled trials have also not found 
an increased risk of MI, stroke with DPP-4i compared to placebo. Two out of the three trials 
have reported no increased risk of heart failure with DPP-4i.  
Aim 2: Using hospitalization for heart failure (HF) as a positive control outcome, explore the use 
of calendar time as an instrumental variable and compare this approach to an active comparator 
new-user study comparing DPP-4i versus TZD (actual treatment received) in sample of Medicare 
beneficiaries without a history of HF or related conditions. 
Hypothesis: Both the instrumental variable and treatment received approach will yield 
similar results of no increased risk of HF with DPP-4i versus TZD. 
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Rationale: DPP-4i and TZD are both second line antihyperglycemic drugs expected to be 
in therapeutic equipoise in a population excluding anyone with clear contraindications. The 
increase in the use of DPP-4i with a simultaneous decrease in TZD use over a short period of 
time also provides an opportunity to use calendar time as an instrumental variable in this setting. 
This is therefore a unique setting where both analytic approaches are expected to perform equally 
well. 
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CHAPTER 2. BACKGROUND AND REVIEW OF LITERATURE 
I. Background 
Type 2 diabetes is a complex metabolic disorder characterized by hyperglycemia because 
of insufficient insulin secretion and resistance to insulin action.17  Cardiovascular safety of 
antidiabetic drugs is a question of great interest invigorated by the ongoing discussions about 
cardiovascular safety of thiazolidinediones. Cardiovascular (CV) disease is a leading cause of 
morbidity and mortality in diabetic patients and management of CV risk factors is critical in 
diabetes care.1 The Food and Drug Administration (FDA) therefore requires an assessment of 
cardiovascular events in antihyperglycemic drug development programs.1 
 Dipeptidyl peptidase 4 inhibitors (DPP-4i) were first introduced in the U.S. in 2006. 
Since then, a number of new drugs in each class have been developed. GLP-1 (glucagon-like 
peptide 1) is one of the two incretin hormones that stimulate the release of insulin from the 
pancreas after food intake in a glucose-dependent manner thereby reducing the average blood 
glucose levels. GLP-1 is degraded within 2-3 minutes by the enzyme dipeptidyl peptidase-4 and 
the DPP-4i act by raising the endogenous levels of GLP-1 by inhibiting the enzyme DPP-4.1 
II. Review of the literature: 
The mechanism of DPP-4 inhibition has been shown to exert cardioprotective effects in 
preclinical models of cardiovascular dysfunction, and short-term studies in human subjects 
demonstrate modest beneficial actions on cardiac function (example, reduction of ischemic area 
at risk with GLP-1 infusion) in subjects with myocardial infarction.18  DPP-4i have demonstrated 
improved glycemic control with beneficial effect of cardiovascular risk factors like decrease in 
 5 
blood pressure, low risk of hypoglycemia and neutral (DPP-4i) weight profile suggesting 
potential CV benefit.19 
 Recently completed randomized controlled trials have examined the CV effects of 
adding DPP-4i versus placebo to existing therapy and found no evidence of increased risk of 
myocardial infarction (MI), stroke and CV death with DPP-4i.2, 3, 4 All these trials met the FDA 
criteria for non-inferiority of these agents over placebo but found no evidence of CV risk 
reduction1-3 This is unlike the observations in previous meta-analyses of about 70 clinical trials 
on DPP-4i agents that found reduced CV risk with DPP-4i compared to placebo or active 
comparators (SU, TZD or metformin).20, 21 The saxagliptin trial (SAVOR-TIMI53) reported a 
27% increased risk of heart failure hospitalizations with the addition of saxagliptin versus 
placebo to existing therapy, while the other two trials on alogliptin (EXAMINE) and sitagliptin 
(TECOS) did not find this effect.2, 3, 4  Pre-clinical data in rats suggest that inhibition of the DPP-
4 enzyme may reduce the rate of heart failure. Moreover, the effect of DPP-4i may be different 
in subgroups with and without heart failure. Brain natriuretic peptides are substrates for DPP-4i 
inhibitors and are much higher in patients with heart failure compared to patients without heart 
failure. Given the observations of the SAVOR-TIMI trial, the FDA has requested the clinical 
trial data from manufacturers of saxagliptin to explore this further.22 Heart failure is a concern 
with older glucose-lowering drugs (example thiazolidinediones) and evaluating heart failure in 
clinical trials of antidiabetic drugs is important as recently suggested.23  Therefore it is of interest 
to compare the incidence of heart failure with DPP-4i versus other agents.24 
 There have been a few observational studies examining the risk of cardiovascular 
outcomes with DPP-4i.7-12, 25  While all studies report no increased relative risk of MI and stroke 
with DPP-4i, the evidence on heart failure is mixed with all but two studies reporting no 
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increased risk. All the studies mainly reported summary relative risk measures but not the 
absolute risk measures which may be important to put the issue in context. Further, several 
studies used a combined pool of non-DPP-4i drugs as the comparator making interpretation of 
the results difficult and less useful for physicians for making treatment decisions. To date there 
has not been any epidemiologic study comparing the incidence of CV events with DPP-4i versus 
clinically relevant active comparators in a US population of older adults with a high prevalence 
of comorbidity and long duration of diabetes, both of which could affect the effects of DPP-4i on 
CV risk. While randomized trials have had an important role in assessing the CV safety of DPP-
4i, all of the trials to date have compared the addition of a DPP-4i versus adding no drug to 
existing therapy which may not necessarily represent real world treatment patterns which involve 
a lot of switching or stopping treatments. Moreover, other than the ongoing trial comparing 
linagliptin to glimepiride (CAROLINA trial),26 all of the completed trials were placebo-
controlled making it difficult to assess the comparative incidence of cardiovascular events 
relative to other second line antihyperglycemic drugs. Finally, the trials have recruited high risk 
populations, largely patients with a prior history of CV events.   
These results may therefore be supplemented by well-designed observational studies 
based on real-world treatment practices that assess comparative incidence of cardiovascular 
events with DPP-4i. We therefore proposed to examine the comparative incidence of CV events 
with DPP-4i relative to other oral therapeutic alternatives SU and TZD. 
In recent years, the use of DPP-4i increased with a corresponding decrease in the use of 
TZDs while SU use was more or less constant. According to a recent analysis 13  of the IMS 
health data examining the market trends of antihyperglycemic drugs, the newly approved drugs, 
particularly the DPP-4i class quickly gained significant market share and was the most 
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commonly prescribed new drug class by 2012.  On the other hand, the use of thiazolidinediones 
decreased by 2012 with the use of pioglitazone reaching only half its peak use in 2008 and 
negligible use of rosiglitazone. DPP-4i and TZD are both second-line antihyperglycemic drugs, 
with intermediate (DPP-4i) to high (TZD) efficacy, low risk of hypoglycemia 14  and comparable 
costs before the generic form of pioglitazone was introduced in August 2012.15 
 The DPP-4i and TZD drugs are therefore expected to be in therapeutic equipoise in a 
population excluding anyone with clear contraindications. The increase in the use of DPP-4i with 
a simultaneous decrease in TZD use over a short period of time also provides an opportunity to 
use calendar time as an instrumental variable (IV) as suggested previously in other settings.16   
According to our knowledge, this is a first unique setting where there exists both an active 
comparator and also a potential IV driven by the antihyperglycemic drug market which enables 
comparison of the two methods. Using hospitalization for heart failure (HF) as a positive control 
outcome we explored the use of calendar time as an IV and compared this approach to an active 
comparator new-user study comparing DPP-4i versus TZD.
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CHAPTER 3. METHODS 
I. Study Designs, Exposure and Comparisons 
For aim 1, we used an active comparator, new-user cohort study design. New-user design 
helps to avoid the biases inherent in the prevalent user design. This design is analogous to a 
head-to-head clinical trial (except that drugs are not assigned by randomization)27 and mimics the 
most relevant clinical decision (‘which treatment to initiate’ rather than ‘treatment or not’). It 
allows synchronizing follow-up in all cohorts which is the basis for sensitivity analyses of 
induction periods. 
We compared DPP-4i with SU and TZD in separate analyses. Metformin is the first-line 
pharmacotherapy for type 2 diabetes. In case of insufficient control of blood glucose levels, one 
of the second-line agents in the table below is added to the treatment regimen.14  Comparing 
DPP-4i to other antidiabetic drugs that are likely to be indicated at a similar stage of diabetes 
progression and severity ensures balance in most confounders at baseline.  
For aim 2, we compared two analytic approaches – ‘actual treatment received’ i.e., DPP-
4i versus TZD and analyses using calendar time as an instrumental variable. Exposure was for 
the former approach was initiation of either DPP-4i or TZD. For the later, an ‘optimal’ IV was 
defined using drug initiation curves and substantive information that included FDA drug safety 
communications about the TZDs.  
II. Data Source 
For both aim 1 and aim 2, we will use a 20% random sample of Medicare beneficiaries 
>65 years with fee-for-service Part A (hospital coverage), B (outpatient medical care) and D 
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(dispensed prescription drugs) enrollment in at least one month during a calendar year from 
January 1, 2007 (2006 for Part A and B) to December 31, 2013. This data contains information 
about demographics characteristics, plan enrollment, diagnoses, procedures and prescription 
drugs for each enrollee. Data is recorded by the International Classification of Diseases, Ninth 
Revision (ICD-9), Current Procedural Terminology-4 (CPT-4) codes, and the Healthcare 
Common Procedure Coding System (HCPCS). Dispensed prescriptions are coded using National 
Drug Codes (NDCs).  
III. Study cohort, eligibility criteria  
For aim 1, we identified two new-user cohort pairs – DPP-4i versus SU (not exposed to 
either DPP-4i or SU in the previous 6 months) and DPP-4i versus TZD (not exposed to either 
DPP-4i or SU in the previous 6 months).  Patients could be on any antihyperglycemic drugs 
other than the drugs compared in the 6 months pre-initiation. For example, in the DPP-4i versus 
SU comparison, patients could be on any drugs except DPP-4i and SU during the washout period. 
A DPP-4i initiator with no previous prescription of SU and TZD would be eligible for inclusion 
in both comparisons. Initiation was defined as the first prescription of the drug with the index 
date defined as the date of dispensing. Patients were required to have at least 6 months of 
continuous Part D enrollment and at least 12 months parts A and B enrollment pre-index. To 
reduce the potential for bias toward the null due to secondary nonadherence, we restricted our 
cohorts to patients with a second prescription for the same drug class dispensed within 6 months 
after the index date and follow-up started from the second fill date. Since TZDs are 
contraindicated in patients with existing heart failure (which can lead to intractable confounding 
by contraindication if not properly accounted for), for all analyses comparing DPP-4i versus 
TZD we further excluded patients with diagnoses of heart failure, hypertensive disease with heart 
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failure and closely related conditions of cardiomyopathy, arrhythmias, chronic kidney disease, 
edema and use of loop diuretics.  
For aim 2, for the ‘treatment initiated’ approach, we identified new-users of DPP-4i or 
TZD as described above from a population without previous diagnoses of heart failure and 
related conditions. Next we defined a cohort of new-users of DPP-4i and TZD for our IV 
analysis. An IV is an observed variable associated with the variation in exposure like randomized 
assignment in a clinical trial.28  To be valid, an IV 1) should be associated with the treatment, 2) 
should be unrelated to patient characteristics and 3) should be related to the outcome only 
through its association with the treatment (exclusion restriction). Additionally, in order to 
estimate the average treatment effect in the ‘compliers’ an additional assumption of 
‘monotonicity’ (no ‘defiers’) should hold. Monotonicity requires that the instrument affects the 
treatment deterministically in one direction.28 
We defined the IV as a binary variable (post versus pre-period) anchored around the time 
of the cross-over of the drug initiation curves (June – September 2010) which was also the time 
when the FDA issued communications about restriction of rosiglitazone and concerns about the 
safety of pioglitazone. In our study, ‘compliers’ are patients whose initial treatment is 
determined by the calendar time in which they initiated treatment – i.e, TZD if initiating before 
the crossover of the drug initiation curves and DPP-4i if initiating after the crossover. We 
identified an ‘optimal’ IV by evaluating the strength of the instrument’s effect on the received 
treatment.16 We examined the instrument in relation to IV assumptions using measured 
covariates, falsification tests and expert knowledge. The binary measure of calendar time was 
decided before examining the effect estimates. 
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IV. Outcomes 
Aim 1 –  
The outcomes for this aim 1 were non-fatal MI, stroke, hospitalization for heart failure 
(HF) and all-cause mortality and a composite CV outcome of non-fatal MI, stroke and all-cause 
mortality based on the outcome definition in the RCTs. Medicare claims data do not include 
information on causes of death and we could not directly identify cardiovascular death. However 
since cardiovascular deaths are responsible for more than half of the deaths in patients with 
diabetes, we used all-cause mortality a proxy in this study.29  MI was defined using International 
Classification of Diseases, Ninth Revision (ICD-9) code 410 in the first or second position of the 
inpatient claims, a definition with a positive predictive value of 94% in a Medicare population.30  
Stroke was defined using ICD-9 codes 430, 431, 433.x1, 434.x1, and 436, located in the first 
position only (specificity 95–97%, sensitivity 74–90%).31  HF hospitalization was defined using 
ICD-9 code 428.xx in the primary position only which has a specificity >98% but a very low 
sensitivity of 21% in a Medicare population.32 
Aim 2 –  
For aim 2, the outcome was hospitalization for HF33 defined using ICD-9 code 428.xx in 
the primary position in inpatient claims as for aim 1. TZDs are known to be associated with an 
increased risk of heart failure.34 While recently reported placebo-controlled SAVOR-TIMI trial 
reported a 27% increased risk of heart failure with saxagliptin, the trials of other DPP-4i 
(EXAMINE and TECOS) indicate no increased incidence of HF with DPP-4i drugs sitagliptin 
and alogliptin (which is >80% of our cohort).2, 3, 35  HF hospitalization is therefore a positive 
control outcome in our study enabling the comparison of performance of the propensity score 
weighting method comparing the ‘actual treatments initiated’ and IV analysis comparing levels 
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of the calendar time instrument. Patients were followed up from the second fill date till the 
earliest of the following – outcome (HF hospitalization), death, end of enrollment or 2 years after 
the index date.  
V. Follow-up 
The primary analysis approach used for aim 1 was ‘as-treated’. Patients were followed 
from the second prescription until the earliest of: the outcome of interest, discontinuation (no 
new prescription for the initiated drug, within days-supply plus a 180 days grace period to allow 
for dose adjustment/irregular use), switching to or augmentation with the comparator drug, non-
end point event (example, stroke would be a non-end point event in the analysis of MI), end of 
enrollment, or December 31, 2013. 
For aim 2, we used an intent-to-treat approach. Patients were followed up from the 
second prescription date till the earliest of the following – outcome (HF hospitalization), death, 
end of enrollment or 2 years after the index date.  
Confounding control and analysis: 
For aim 1, we used propensity scores (PS) to control for measured confounding. Using 
baseline variables (comorbidities, medication use, health care utilization) measured before 
initiation, we predicted the probability for initiating DPP-4i versus SU and DPP-4i versus TZD 
for each patient (the PS) using two separate logistic regression models.36  We then assigned a 
weight of 1 to the treated (DPP-4i) and a weight of (PS/(1-PS)) to SU and TZD. Such weighting 
creates pseudo-populations of SU and TZD initiators with similar covariate distribution as in 
DPP-4i initiators. This covariate balance across groups allows us to estimate the unconfounded 
treatment effect in a population of patients similar to those actually initiating DPP-4i.37, 38  Our 
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weighted analysis thus answers the question “what would have happened to patients who 
initiated DPP-4i if they had initiated SU or TZD, instead”. 
Competing risks arise when the occurrence of one event precludes the occurrence of 
other events. In our study of older adults, mortality is a competing event and censoring patients 
who die and analyzing the data using standard Cox proportional hazards models yields biased 
estimates because this type of censoring may be ‘informative’.39  We therefore used weighted 
cumulative incidence curves accounting for competing risk by death to estimate the risk, risk 
differences (RD) and risk ratios (RR) for non-fatal MI, stroke and hospitalization for HF among 
initiators of DPP-4i versus comparators.39  We obtained confidence intervals by bootstrapping 
1000 replicates. We analyzed the composite outcome of non-fatal MI, stroke or all-cause 
mortality using traditional weighted Cox models. 
Analyses were repeated in pre-specified subgroups based on history of CV disease 
(diagnoses of MI, stroke, angina, other ischemic disease, atherosclerosis for the DPP-4i versus 
TZD comparison and the above diagnoses plus heart failure related diagnoses for the DPP-4i 
versus SU comparison). 
Under the ‘treatment received’ approach, we used inverse probability of treatment (IPTW) 
weighting using PS to control for confounding. PS for DPP-4i versus TZD was estimated using 
baseline covariates without including the year of initiation in the model as it can increase the 
variability of effect estimates and can increase bias in case of unmeasured confounding. 36, 40, 41 
We then assigned a weight of 1/PS to DPP-4i and a weight of (1/(1-PS)) to TZD and stabilized 
both groups by marginal prevalence of the treatment actually received.42 Such inverse probability 
of treatment (IPTW) weighting creates a pseudo-population in which the association between 
covariates and treatment is removed by the weighting described above. Under the assumption of 
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no unmeasured confounding this method allows us to contrast two scenarios: “what would have 
happened if the entire population initiated DPP-4i’ versus ‘“what would have happened if the 
entire population initiated TZD’.42  Using IPTW weighted Kaplan Meier curves we then 
estimated the RDs for HF hospitalization using treatment as the strata variable.  
The effect of the IV levels on HF hospitalization was observed by the IV estimates of RD 
scaled by the IV strength to estimate the average treatment effect among the ‘compliers’. Next 
we generated covariate-adjusted IV estimates of the RD using weighted Kaplan-Meier methods 
analogous to the IPTW weighted methods described above and scaled this by the strength of the 
instrument. Under this approach, we first predicted the probability (PP) of the instrument as a 
function of baseline covariates and assigned a weight of 1/PP to the ‘post’ period and 1/(1-PP) to 
the ‘pre’ period and stabilized the weights by the marginal prevalence of the instrument. 
VI. Sensitivity Analysis 
Aim 1 –  
The following sensitivity analyses were performed. First, to increase the probability of 
cardiovascular cause of death, we excluded the deaths of patients with codes for metastatic 
cancer anytime during follow-up. Second, since SU are older drugs and to ensure that patients 
were indeed treated with SU as second line drugs (rather than first line therapy), we repeated the 
DPP-4i versus SU analyses requiring patients to have at least one metformin prescription in the 6 
months before the index date. Finally we repeated all analyses using an intent-to-treat approach 
where patients were not censored for treatment changes but followed from the second 
prescription to the earliest of the outcome, non-event end point, end of enrollment, or December 
31, 2013. 
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Aim 2 –  
The following sensitivity analyses were performed for aim 2. First, propensity score 
models used the full study population and we performed sensitivity analyses in the reduced 
instrumental variable cohort to evaluate selection differences that may have been introduced 
based on instrumental variable exclusions. Next we performed a sensitivity analysis restricting 
the study cohort to patients who initiated DPP-4i or TZD between July 2007 and December 2011, 
with follow-up allowed through December 2013. This approach excluded anyone who initiated 
therapy during or after January 2012, who would not have the potential for a 2-year follow-up 
before the end of the study (and therefore potentially violate the assumption of ‘non-informative’ 
censoring i.e., the assumption that patients who drop out of the study should do so for reasons 
unrelated to the study).43  Finally we performed additional analyses with different definitions of 
the instrument (IV defined using a cut-point and by comparing periods with maximum separation; 
described in supplemental figures 2 and 3). 
All analyses were performed with the SAS software, 9.3 version.
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CHAPTER 4. COMPARITIVE INCIDENCE OF CARDIOVASCULAR EVENTS 
IN OLDER ADULTS INITIATING DIPEPTIDYL PEPTIDASE 4 INHIBITORS 
VERSUS THERAPEUTIC ALTERNATIVES 
I. Introduction 
In the United States over 25% of the population 65 years or older has diabetes.44 
Cardiovascular (CV) disease is a leading cause of morbidity and mortality in diabetes patients, 
with the risk increasing with age.45  While improved glycemic control by antihyperglycemic 
drugs reduces microvascular complications, uncertainty remains regarding risk reduction for CV 
events. International agencies now require a thorough assessment of CV risk in 
antihyperglycemic drug development programs.46,47  
The dipeptidyl peptidase-4 inhibitors (DPP-4i) are relatively new antihyperglycemic 
drugs that were incorporated into diabetes treatment algorithms as second line therapy since 
2011. These drugs have good tolerability, low risk of hypoglycemia and are weight neutral 
compared to other second line drugs.14 Three randomized placebo-controlled trials (RCT) have 
recently evaluated the CV safety of DPP-4i (saxagliptin, alogliptin and sitagliptin) in high-risk 
patients with type 2 diabetes.2-4  All RCTs found no increase in the risk of non-fatal myocardial 
infarction, stroke, CV death with adding a DPP-4i agent versus placebo to existing therapy. 
However, the saxaglipin trial found an increased risk of hospitalization for heart failure, whereas 
the other two trials did not find any association between DPP-4i treatment and heart failure.2 
 While randomized  trials have had an important role in assessing the CV safety of DPP-
4i, all the trials to date have compared the addition of a DPP-4i versus adding no drug to existing 
therapy which may not represent real world treatment patterns which involve a lot of switching 
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or stopping treatments. Moreover, other than the ongoing trial comparing linagliptin to 
glimepiride (CAROLINA),26 all the completed trials were placebo-controlled making it difficult 
to assess the comparative incidence of cardiovascular events relative to therapeutic alternatives. 
Finally, the trials have recruited high risk populations, largely patients with a prior history of CV 
events.   
Observational studies examining CV risk with DPP-4i report no increased relative risk of 
myocardial infarction and stroke with DPP-4i, but the evidence on heart failure is mixed.7-12, 25 
These studies mainly reported summary relative risk measures but not the absolute risk measures 
which may be important to put the issue in context. Further, several studies used a combined 
pool of non-DPP-4i drugs as the comparator making the results less useful for physicians for 
making treatment choices. To date there has not been any epidemiologic study comparing the 
incidence of CV events with DPP-4i versus clinically relevant comparators in a US population of 
older adults with a high prevalence of comorbidity and long duration of diabetes, both of which 
could affect the effects of DPP-4i on CV risk.  
We therefore compared the relative and absolute risk of CV outcomes among initiators of 
DPP-4i versus relevant oral drug alternatives sulfonylureas (SU) and thiazolidinediones (TZD) 
using a 20% sample of the Medicare fee-for-service beneficiaries. Specifically, we examined the 
risk of non-fatal myocardial infarction (MI), stroke, hospitalization for heart failure (HF) and a 
composite outcome including MI, stroke, and all-cause mortality. 
II. Methods 
Study Population 
We conducted an active-comparator new-user cohort study using a 20% random sample 
of Medicare beneficiaries >65 years with fee-for-service Part A, B and D enrollment in at least 
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one month during a calendar year from January 1, 2007  to December 31, 2013.  This dataset 
contains information about demographics, enrollment, diagnoses, procedures and prescription 
drugs for each enrollee and has been previously used to study antihyperglycemic drugs.49-51 
From this population, we identified two new-user active-comparator cohort pairs 
(TABLE 4.19, TABLE 4.20) mimicking a clinical treatment decision:52  1. DPP-4i versus SU 
(not exposed to either DPP-4i or SU in the previous 6 months) and 2. DPP-4i versus TZD (not 
exposed to either DPP-4i or TZD in the previous 6 months). Initiation was defined as the first 
prescription of the drug after a 6 month washout. Patients were allowed to be on any drugs 
except the drugs compared. A DPP-4i initiator with no previous prescription of SU and TZD 
would be eligible for inclusion in both comparisons.  Patients were required to have at least 6 
months of continuous Part D enrollment and at least 12 months parts A and B enrollment pre-
initiation. To reduce the potential for bias toward the null due to secondary nonadherence, we 
restricted our cohorts to patients with a second prescription for the same drug class dispensed 
within 6 months after initiation and follow-up started from the second fill date. Since TZDs are 
contraindicated in patients with HF (which can lead to intractable confounding by 
contraindication), for DPP-4i versus TZD analyses we further excluded patients with diagnoses 
of HF and related conditions (cardiomyopathy, arrhythmias, chronic kidney disease, edema and 
loop diuretics use).  
Outcomes 
The outcomes assessed were non-fatal MI, stroke, HF hospitalization and all-cause 
mortality and a composite outcome of non-fatal MI, stroke and all-cause mortality based on the 
outcome definition in the RCTs. Medicare claims do not include information on causes of death 
and we could not identify cardiovascular death. However since cardiovascular deaths account for 
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>50% deaths in diabetes patients, we used all-cause mortality as proxy.29,53  MI was defined 
using International Classification of Diseases, Ninth Revision (ICD-9) code 410 in the first or 
second position of the inpatient claims (definition with a positive predictive value of 94% in a 
Medicare population).30  Stroke was defined using ICD-9 codes 430, 431, 433.x1, 434.x1, and 
436, located in the first position (specificity 95–97%, sensitivity 74–90%).31  HF hospitalization 
was defined using ICD-9 code 428.xx in the primary position  which has a specificity >98% but 
a very low sensitivity of 21% in a Medicare population.32 
Patients were followed from the second prescription until the earliest of: the outcome of 
interest, discontinuation, switching to or augmentation with the comparator drug, non-end point 
event (example, stroke is a non-end point event in the analysis of MI), end of enrollment, or 
December 31, 2013.  
Confounding control and analysis 
We used propensity scores (PS) to control for measured confounding. Using variables in 
tables 1 and 2 measured before initiation, we predicted the probability for initiating DPP-4i 
versus SU and DPP-4i versus TZD for each patient (PS) using two separate logistic regression 
models.36 We then assigned a weight of 1 to DPP-4i and a weight of (PS/(1-PS)) to SU and TZD. 
Such weighting creates pseudo-populations of SU and TZD initiators with similar covariate 
distribution as in DPP-4i.37, 38 Our weighted analysis thus answers the question “what would have 
happened to patients who initiated DPP-4i if they had initiated SU or TZD, instead”.42 
Competing Risk 
Competing risks arise when the occurrence of one event precludes the occurrence of 
other events. In our study of older adults, mortality is a competing event and standard Cox 
models censoring patients who die yield biased estimates because this type of censoring may be 
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‘informative’.39  We therefore used weighted cumulative incidence curves accounting for 
competing risk by death to estimate the risk, risk differences (RD) and risk ratios (RR) for non-
fatal MI, stroke and HF hospitalizations among initiators of DPP-4i versus comparators.39  We 
obtained confidence intervals by bootstrapping 1000 replicates. We analyzed the composite 
outcome of non-fatal MI, stroke or all-cause mortality using traditional weighted Cox models. 
Subgroup and Sensitivity analyses: 
Analyses were repeated in pre-specified subgroups based on CVD history. Several 
sensitivity analyses were performed. To increase the probability of CV death, we excluded the 
deaths of patients with codes for metastatic cancer anytime during follow-up. Since SU are older 
drugs and to ensure that patients were indeed treated with SU as second line drugs (rather than 
first-line), we repeated the DPP-4i versus SU analyses requiring patients to have at least one 
metformin prescription in the 6 months before initiation. Finally repeated all analyses using an 
intent-to-treat approach where patients were not censored for treatment changes but followed 
from the second prescription to the earliest of the outcome, non-event end point, end of 
enrollment, or December 31, 2013. 
III. Results 
For the DPP-4i versus SU comparison (TABLE 4.1), there were 44,771 DPP-4i and 
119,436 SU initiators. Compared with the DPP-4i, SU initiators were slightly older, less likely to 
have hyperlipidemia, diabetes complications, less likely to be on metformin or other 
antihyperglycemic medications, statins, and less likely to have had influenza vaccinations and 
lipid panels at baseline. For the DPP-4i versus TZD comparison (TABLE 4.2), there were 26,198 
DPP-4i and 18,842 TZD initiators without previous HF/related diagnoses (excluded because 
TZD are contraindicated in those with pre-existing HF).54 TZD initiators were generally more 
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comparable with DDP4-i initiators than SU initiators. Compared with the DPP-4i initiators, the 
TZD initiators were nevertheless more likely to be male and non-white. TZD initiators were less 
likely to have hyperlipidemia at baseline and less likely to get influenza vaccinations and lipid 
panels compared to DPP-4i initiators. After weighting all covariates in the weighted TZD and 
SU pseudo-populations were identical to the distribution of the DPP-4i initiators.  
For the DPP-4i versus SU comparison, based on 4,720 events (725 MI, 593 stroke and 
3,770 deaths) among DPP-4i initiators and 20,274 events (2,765 MI, 2,209 stroke and 17,046 
deaths) among SU initiators, the adjusted hazard ratio was 0.83 (0.80, 0.86) (TABLE 4.3, 
FIGURE 4.1). This was mainly driven by death (FIGURE 4.2) rather than MI and stroke for 
which risks were approximately 1% at the median of ~1 year of treatment (FIGURE 4.3). The 
adjusted RD per 100 patients for MI comparing DPP-4i versus SU ranged from -0.27 (-0.46, -
0.06) in year 1 to -0.78 (-1.62, 0.12) in year 5 and ranged from -0.11 (-0.23, 0.03) to -0.81 (-1.30, 
-0.22) for stroke (TABLE 4.4,TABLE 4.5) indicating no meaningful difference in the risk of MI 
or stroke between DPP-4i and SU. In the subgroup without prior CVD, the adjusted risks of MI 
and stroke for both DPP-4i and SU groups were <1% at 1 year after initiation and the magnitudes 
of RDs were <1 per 100 patients (TABLE 4.6, TABLE 4.7, FIGURE 4.4). In the subgroup with 
prior CVD, the risks for MI and stroke were slightly higher (~1.5% at 1 year), but the magnitude 
of RD per 100 patients was <1 (FIGURE 4.4, TABLE 4.8, TABLE 4.9). No increased risk of HF 
hospitalization was observed with DPP-4i versus SU (FIGURE 4.5). 
For DPP-4i versus TZD, based on 1,760 events among DPP-4i initiators and 1,466 events 
among TZD initiators the adjusted HR for the composite outcome was 0.94 (0.88, 1.01) 
(FIGURE 4.1, TABLE 4.3). The MI risk for both DPP-4i and TZD groups was ~1% at 1 year 
after initiation with magnitude of RDs <1 per 100 patients (TABLE 4.10, TABLE 4.11). In the 
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subgroup without prior CVD, the 1-year risks of MI and stroke were <1% for DPP-4i and TZD 
(TABLE 4.12, TABLE 4.13, FIGURE 4.3). In the subgroup with prior CVD, the 1-year risks 
were >1% for MI and stroke for both DPP-4i and TZD (FIGURE 4.6,TABLE 4.14, TABLE 
4.15). The RD per 100 patients for HF hospitalization comparing DPP-4i versus TZD were 
between 0 and -1 during the study period (TABLE 4.16, FIGURE 4.5).  
Sensitivity analyses after excluding metastatic cancer deaths from all-cause mortality 
(which accounted for 14-16% of deaths in all treatment groups) did not change the results 
(TABLE 4.17). When we restricted the study population to patients who had a metformin script 
in the 6 months before initiation of DPP-4i or SU, the adjusted HR of the composite outcome 
was 0.77 (0.74, 0.81) and again no difference in individual risks of MI or stroke between DPP-4i 
or SU as evinced by 1-year RDs <1 per 100 patients. Additional analyses using an intent-to-treat 
approach did not change the results (TABLE 4.18). 
IV. Discussion and Conclusions 
We found no evidence of an increased short-term risk of CV events with DPP-4i versus 
SU or TZD in our new-user active-comparator cohort study based on a 20% random sample of 
all US Medicare fee-for-service beneficiaries 2007-2013. The results were consistent across 
subgroups based on prior CVD and several sensitivity analyses. The individual risks of MI and 
stroke at 1 year after initiation in the subgroup with prior CVD (just above 1%) were slightly 
higher than the subgroup without prior CVD (about 0.7%), but the risk differences in either 
subgroups for DPP-4i versus comparators were small (<1 per 100 patients). The apparent 
decreased risk of the composite CV outcome with DPP-4i versus SU is mainly driven by all-
cause mortality. While there is debate about increased risk of all-cause mortality with SU, the 
theoretical risk differs based on which SU agent is used.  
 23 
More information on the comparative risk with DPP-4i versus SU will be added once the 
CAROLINA trial comparing  linagliptin with glimepiride is completed.26, 55, 56  Our results of no 
increased risk of MI and stroke with DPP-4i are consistent with the RCTs on saxagliptin 
(SAVOR-TIMI), alogliptin (EXAMINE) and sitagliptin (TECOS) which found no increased risk 
of MI, stroke with DPP-4i versus placebo in high risk populations.2-4  
We did not observe an increased risk of HF hospitalization with DPP-4i versus SU. 
While the EXAMINE and TECOS trials did not find an increased HF risk with alogliptin and 
sitagliptin respectively, the SAVOR-TIMI 53 trial reported a 27% increased risk of HF 
hospitalization with saxagliptin versus placebo. Several factors could explain the discrepancy. 
First, the SAVOR-TIMI 53 examined saxagliptin alone while our DPP-4i cohort mainly 
consisted of sitagliptin initiators (~75%) and sample size was not sufficient to study saxagliptin 
alone. Second, the treatment duration in our study was shorter than in the trial. Observational 
studies examining HF risk with DPP-4i using different designs, populations and comparators 
report mixed results. Two studies reported a reduced rate of HF compared to other anti-
hyperglycemic drugs9, 12, three studies suggest no difference in effect8, 10, 57, while two studies 
reported increased HF risk with DPP-4i compared to other antihyperglycemic drugs.7, 25 Most of 
these studies used a heterogeneous comparator of ‘all other antihyperglycemic drugs’ makes 
interpretation of results hard particularly in cases where the risks differed greatly depending on 
the comparator.7, 11, 12, 25, 57 One study that reported increased risk of HF compared sitagliptin 
initiators to matched controls who were prevalent users of antihyperglycemic therapy which 
could bias the results due to prevalent users possibly being tolerant to other antihyperglycemic 
therapy.25 Some clinical studies on the other hand, have suggested a protective role of DPP-4i in 
the pathogenesis of CHF.58, 59 
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Since TZDs are known to be associated with an increased HF risk, we used HF 
hospitalization as a positive control outcome in the DPP-4i versus TZD analysis expecting no 
increased risk with DPP-4i relative to TZD and that is what we observed. Taken together the 
evidence from our study and existing literature suggests that there is no concern of increased risk 
of HF hospitalizations with DPP-4i.  
A strength of our study is the use of a new-user active-comparator cohort design which is 
analogous to a head-to-head clinical trial and answers the more relevant question of ‘which 
second-line treatment to initiate’ rather than ‘treatment or not’.27  Specifically, we identified 
initiators of DPP-4i or comparators after 6 months without use of DPP4i or comparator and 
covariates were measured before initiation thereby avoiding the problem of controlling for 
covariates potentially affected by treatment.27  The good balance of measured covariates 
achieved by the study design implies that unmeasured covariates could also be balanced, 
although this cannot be proven. The balance of measured covariates was further improved by PS 
weighting and reassures us about absence of confounding by these covariates. We also used 
specific comparator groups and reported results separately for each comparison unlike a few 
other observational studies where the comparator group consisted of ‘all other antihyperglycemic 
drugs’ making interpretation difficult. Our study also raises an important consideration about 
which is the best comparator for a second line antihyperglycemic drug. As mentioned above, 
since TZDs are contraindicated in patients with existing HF, for this comparison we had to 
exclude patients with previous diagnoses of HF or related conditions in order to identify patients 
with treatment equipoise. On the other hand, more initiators of DPP-4i compared to SU had 
baseline use of metformin and long acting insulin possibly suggesting that the SU group 
consisted of newer diabetes patients compared to DPP-4i. To address this, we repeated the 
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analyses requiring a prescription of metformin (first line drug) at baseline to ensure that patients 
with second line therapy were being compared. Researchers should be cognizant of such 
differences and identify ways to increase treatment equipoise, i.e., patients in whom the choice of 
treatments not driven by predictors of the risk for the outcome. 
Following caveats should be considered. First, the time-on-treatment in our primary as-
treated analysis was short (median ~1 year) but that is mostly a function of the real-world 
treatment dynamics. Second, since Medicare claims do not contain information on causes of 
death, we could not identify cardiovascular death. Sensitivity analyses excluding deaths in 
patients with metastatic cancer to increase the contribution of cardiac death to all-cause mortality 
did not change results. Third, given the absence of clinical measures it is hard to identify HF 
using claims data and our definition of HF hospitalization had a near perfect specificity (which 
yields unbiased relative risks) but a low sensitivity which will lead to an underestimation of 
absolute risks. Fourth, since occurrence of one CV event during follow-up might affect the 
incidence of a subsequent CV event, (example, MI can affect the risk of stroke), we censored 
patients at non-end point CV events. This could theoretically lead to ‘competing risk’ from the 
non-end point event, but such censoring was extremely rare in our study. Finally we were not 
able to measure and adjust for lifestyle variables like smoking and body mass index directly 
(BMI). However we adjusted for codes for tobacco use and chronic obstructive pulmonary 
disease as proxies for smoking and smoking is unlikely to meaningfully affect the choice of 
second line treatments. We also previously found that BMI does not affect the choice of 
initiation of DPP-4i versus SU and TZD and therefore is unlikely to be a confounder in this 
setting.60 
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 In summary, we did not observe an increased short-term risk of CV events with DPP-4i 
versus relevant oral second line diabetes drugs in a population of older adults. Along with the 
RCT results, our results based on real-world drug use and effects are relevant to physicians for 
making antihyperglycemic treatment choices.  
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V. Tables and Figures 
TABLE 4.1. Characteristics of initiatorsa of dipeptidyl peptidase-4 inhibitors and sulfonylureas : 
Medicare claims data 2006 – 2013 
  DPP-4i (44,771) SU (N = 119,436) weighted 
SU b 
  N % N % % 
66 to 75 years old 24,839 55.5 63,885 53.5 55.7 
76 to 85 years old 15,229 34.0 40,767 34.1 33.8 
86 years and above 4,703 10.5 14,784 12.4 10.5 
Male 17,520 39.1 50,230 42.1 39.0 
White 33,076 73.9 92,933 77.8 73.9 
Black 4,681 10.5 14,030 11.8 10.4 
Other 7,014 15.7 12,473 10.4 15.7 
Baseline cardiovascular comorbidities c 
Diagnosis of acute myocardial infarction 1,489 3.3 4,694 3.9 3.4 
Diagnosis of old myocardial infarction 2,713 6.1 7,566 6.3 6.1 
Angina 3,306 7.4 7,186 6.0 7.4 
Cardiomyopathy 2,606 5.8 7,268 6.1 5.8 
Arrhythmia, syncope or pacemaker 12,876 28.8 35,347 29.6 28.9 
Heart failure 9,900 22.1 27,926 23.4 22.3 
Hyperlipidemia/ lipid disorder 37,726 84.3 91,849 76.9 84.4 
Hypertension 40,849 91.2 106,725 89.4 91.3 
Hypertensive heart disease with heart 
failure 
1,687 3.8 3,593 3.0 3.9 
Diagnosis of Stroke or TIA 3,614 8.1 10,480 8.8 8.2 
Other acute and sub-acute forms of 
ischemic heart disease 
1,880 4.2 4,844 4.1 4.3 
Other baseline comorbiditiesc 
Obesity diagnosis 658 1.5 1,599 1.3 1.5 
Diabetic nephropathy 3,943 8.8 8,835 7.4 8.9 
Diabetic neuropathy 9,256 20.7 19,045 16.0 20.9 
Diabetic retinopathy 6,959 15.5 13,768 11.5 15.7 
Bone fractures 3,171 7.1 8,496 7.1 7.2 
Chronic obstructive pulmonary disease 9,637 21.5 26,968 22.6 21.4 
Cancer (Non-Skin) 7,746 17.3 20,207 16.9 17.2 
Chronic kidney disease (CKD) 8,706 19.5 23,177 19.4 19.6 
CKD Stage1 518 1.2 1,131 1.0 1.2 
CKD Stage2 1,155 2.6 2,693 2.3 2.6 
CKD Stage3 4,683 10.5 11,240 9.4 10.6 
CKD Stage4 1,355 3.0 3,415 2.9 3.1 
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CKD Stage5 283 0.6 776 0.7 0.6 
End Stage renal disease 698 1.6 2,067 1.7 1.6 
Chronic lung diseases 8,375 18.7 21,884 18.3 18.8 
Connective tissue diseases 15,209 34.0 35,193 29.5 34.0 
Dementia 3,833 8.6 12,189 10.2 8.6 
Depression 7,608 17.0 19,477 16.3 17.0 
Edema 7,912 17.7 20,059 16.8 17.7 
Foot ulcers 5,072 11.3 12,054 10.1 11.4 
Inflammatory GI diseases 412 0.9 1,051 0.9 0.9 
Liver disease 2,891 6.5 6,707 5.6 6.5 
Other chronic ischemic heart disease 17,683 39.5 45,214 37.9 39.6 
Other neurological disorders 8,739 19.5 19,345 16.2 19.6 
Other ocular disorders 18,662 41.7 43,968 36.8 41.7 
Other renal disorders 5,355 12.0 15,730 13.2 12.1 
Pancreatitis 557 1.2 1,634 1.4 1.3 
Peripheral vascular disease 
(claudication) 
7,795 17.4 18,526 15.5 17.4 
Proteinuria 1,707 3.8 3,724 3.1 3.9 
Tobacco use diagnosis 4,363 9.8 12,927 10.8 9.7 
Urinary tract infection/cystitis 12,128 27.1 30,175 25.3 27.2 
Upper Respiratory 13,018 29.1 31,451 26.3 29.2 
Alcoholism 77 0.2 287 0.2 0.2 
Aortic aneurysm 1,228 2.7 3,224 2.7 2.7 
Dialysis 399 0.9 1,306 1.1 0.9 
Baseline medication use d 
Metformin 28,526 63.7 65,528 54.9 64.3 
Sulfonylureas 11,502 25.7 17,845 14.9 25.8 
Glucagon-like peptide-1 agonists 805 1.8 1,444 1.2 1.9 
Long acting insulin 8,529 19.1 16,046 13.4 19.5 
Short acting insulin 4,311 9.6 9,244 7.7 9.7 
Anticholinergic 1,222 2.7 3,760 3.2 2.7 
Statins 28,295 63.2 67,347 56.4 63.4 
Angiotensin converting enzyme 
inhibitors 
17,146 38.3 50,479 42.3 38.3 
Angiotensin receptor blockers 9,733 21.7 19,138 16.0 22.0 
Beta blockers 21,990 49.1 58,999 49.4 49.3 
Calcium channel blockers 14,587 32.6 39,654 33.2 32.7 
Loop diuretics 12,531 28.0 35,898 30.1 28.1 
Other diuretics 18,310 40.9 47,183 39.5 41.0 
Healthcare utilization variablesc 
Blood tests 4,348 9.7 10,178 8.5 9.8 
Influenza vaccinations 25,334 56.6 63,769 53.4 56.6 
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Lipid panels 39,101 87.3 95,216 79.7 87.5 
Mammogram 9,971 22.3 22,466 18.8 22.4 
a Initiation defined as no dispensed prescriptions for DPP-4i or SU during the 6 months before 
initiation and filling a second prescription of the same drug/drug class within 6 months after the 
first prescription.  
b Pseudo-population of SU initiators weighted to the distribution of covariates of the DPP-4i 
initiators using the propensity score to balance covariates (and therefore control for 
confounding).  
c Measured in the 12 months before drug initiation.  
d Measured in the 6 months before drug initiation 
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TABLE 4.2. Characteristics of initiatorsa of dipeptidyl peptidase-4 inhibitors and 
thiazolidinediones : Medicare claims data 2006 – 2013 
  DPP-4i (26,198) TZD (N = 18,842) weighted TZDb 
  N % N % % 
66 to 75 years old 16,975 64.80 12,387 65.74 64.60 
76 to 85 years old 7,559 28.85 5,339 28.34 28.87 
86 years and above 1,664 6.35 1,116 5.92 6.54 
male 10,390 39.66 8,217 43.61 39.64 
white 19,777 75.49 13,444 71.35 75.55 
black 2,338 8.92 1,978 10.50 8.88 
other 4,083 15.59 3,420 18.15 15.57 
Baseline cardiovascular comorbiditiesc 
Diagnosis of acute myocardial 
infarction 
221 0.84 98 0.52 0.86 
Diagnosis of old myocardial 
infarction 
581 2.22 304 1.61 2.27 
Angina 921 3.52 490 2.60 3.53 
Hyperlipidemia/ lipid disorder 21,843 83.38 14,370 76.27 83.44 
Hypertension 22,895 87.39 15,615 82.87 87.36 
Diagnosis of Stroke or TIA 1,222 4.66 753 4.00 4.66 
Other acute and sub-acute forms 
of ischemic heart disease 
405 1.55 195 1.03 1.55 
Other baseline comorbiditiesc 
Obesity diagnosis 253 0.97 119 0.63 1.00 
Diabetic nephropathy 776 2.96 532 2.82 2.95 
Diabetic neuropathy 3,996 15.25 2,393 12.70 15.53 
Diabetic retinopathy 3,625 13.84 2,436 12.93 13.91 
Bone fractures 1,062 4.05 740 3.93 4.20 
Chronic obstructive pulmonary 
disease 
2,885 11.01 1,963 10.42 11.09 
Cancer (Non-Skin) 3,962 15.12 2,342 12.43 15.16 
Chronic lung diseases 2,936 11.21 1,824 9.68 11.19 
Connective tissue diseases 6,946 26.51 4,139 21.97 26.74 
Dementia 1,279 4.88 871 4.62 4.98 
Depression 3,090 11.79 1,849 9.81 11.85 
Foot ulcers 1,823 6.96 1,094 5.81 7.06 
Inflammatory GI diseases 169 0.65 126 0.67 0.62 
Liver disease 1,367 5.22 804 4.27 5.29 
Other neurological disorders 3,615 13.80 2,162 11.47 13.85 
Other ocular disorders 10,371 39.59 6,327 33.58 39.69 
Other renal disorders 574 2.19 342 1.82 2.18 
Pancreatitis 197 0.75 133 0.71 0.77 
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Peripheral vascular disease 
(claudication) 
2,523 9.63 1,537 8.16 9.78 
Proteinuria 598 2.28 355 1.88 2.27 
Tobacco use diagnosis 1,653 6.31 915 4.86 6.32 
Urinary tract infection/cystitis 4,920 18.78 2,920 15.50 18.93 
Upper Respiratory 6,627 25.30 4,101 21.77 25.38 
Alcoholism 23 0.09 21 0.11 0.09 
Aortic aneurysm 421 1.61 233 1.24 1.64 
Baseline medication used 
Metformin 19,348 73.85 13,292 70.54 73.74 
Sulfonylureas 13,628 52.02 10,193 54.10 52.01 
Glucagon-like peptide-1 agonists 468 1.79 308 1.63 1.85 
Long acting insulin 2,956 11.28 2,175 11.54 11.44 
Short acting insulin 1,077 4.11 822 4.36 4.16 
Anticholinergic 373 1.42 308 1.63 1.40 
Statins 15,814 60.36 11,537 61.23 60.59 
Angiotensin converting enzyme 
inhibitors 
10,098 38.54 7,894 41.90 38.53 
Angiotensin receptor blockers 4,521 17.26 2,713 14.40 17.34 
Beta blockers 9,618 36.71 6,113 32.44 36.57 
Calcium channel blockers 7,090 27.06 4,743 25.17 27.11 
Other diuretics 10,609 40.50 7,423 39.40 40.41 
Healthcare utilization variablesc 
Blood tests 2,411 9.20 1,611 8.55 9.22 
Influenza vaccinations 14,713 56.16 9,603 50.97 56.36 
Lipid panels 23,379 89.24 16,076 85.32 89.32 
Mammogram 6,517 24.88 3,974 21.09 24.98 
a Initiation defined as no dispensed prescriptions for DPP-4i or TZD during the 6 months 
before initiation and filling a second prescription of the same drug/drug class within 6 months 
after the first prescription. For the DPP-4i versus TZD analysis, patients with prevalent 
diagnosis of heart failure, hypertensive disease with heart failure, chronic kidney disease, 
edema and use of loop diuretics were excluded.  
b Pseudo-population of SU initiators weighted to the distribution of covariates of the DPP-4i 
initiators using the propensity score to balance covariates (and therefore control for 
confounding).  
cMeasured in the 12 months before drug initiation.  
dMeasured in the 12 months before drug initiation 
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TABLE 4.3. Number of initiators, events (composite of nonfatal myocardial infarction, stroke and death), treatment duration, person–
years, event rates and crude and adjusted hazard ratios for DPP-4i versus comparators in the entire population as well as subgroups 
based on prior cardiovascular disease   
Comparison Treatment 
Number 
of new-
usersa 
events 
Treatment 
duration b 
interquartile 
range (median) 
Total 
person-
years 
Incidence 
(per 100 
person 
years) 
Unadjusted HR 
(95% CI) c 
Adjusted HR 
(95%CI) d 
Entire population 
DPP-4i vs SU DPP-4ie 44,771 4,720 0.58 - 1.96 (1.04) 63,709 7.4 0.71 (0.69, 0.74) 0.83 (0.80, 0.86) 
  SU 119,436 20,274 0.62 - 2.39 (1.21) 197,245 10.3 1.00 (reference) 1.00 (reference) 
  
DPP-4i vs TZD DPP-4ie 26,198 1,760 0.60 - 2.08 (1.09) 39,553 4.4 0.93 (0.87, 1.00) 0.94 (0.88, 1.01) 
  TZD 18,842 1,466 0.68 - 2.27 (1.17) 30,635 4.8 1.00 (reference) 1.00 (reference) 
Subgroup without CVD at baseline 
DPP-4i vs SU DPP-4ie 15,602 792 0.59 - 2.05 (1.11) 23,517 3.4 0.67 (0.62, 0.73) 0.78 (0.72, 0.85) 
  SU 41,934 3,847 0.67 - 2.64 (1.33) 75,520 5.0 1.00 (reference) 1.00 (reference) 
  
DPP-4i vs TZD DPP-4ie 17,742 994 0.61 - 2.10 (1.11) 27,198 3.6 0.88 (0.80, 0.96) 0.91 (0.83, 1.00) 
  TZD 13,725 956 0.69 - 2.32 (1.21) 22,816 4.2 1.00 (reference) 1.00 (reference) 
Subgroup with CVD at baseline 
DPP-4i vs SU DPP-4ie 26,873 3,722 0.58 - 1.89 (0.99) 36,691 10.1 0.72 (0.70, 0.75) 0.83 (0.80, 0.86) 
  SU 71,052 15,322 0.59 - 2.21 (1.12) 110,013 13.9 1.00 (reference) 1.00 (reference) 
  
DPP-4i vs TZD DPP-4ie 25,601 1,683 0.61 - 2.08 (1.09) 38,774 4.3 0.93 (0.87, 0.99) 0.94 (0.87, 1.01) 
  TZD 18,445 1,406 0.68 - 2.27 (1.18) 30,017 4.7 1.00 (reference) 1.00 (reference) 
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DPP-4i - Dipeptidyl peptidase 4 inhibitors, TZD - thiazolidinediones, SU - sulfonylureas, CVD - cardiovascular disease  
a Initiation defined as no dispensed prescriptions of the drugs being compared during the 6 months before initiation and filling a second 
prescription of the same drug/drug class within 6 months after the first prescription.   
b Patients followed up from the 2nd prescription to the earliest of the following: outcome of interest,  
cHazard ratios and their 95 % confidence intervals from Cox proportional hazards models for the composite outcome with baseline 
treatment as the only independent covariate.  
d Hazard ratios adjusted for variables in Table 1 and 2 using propensity score weighting (standardized to DPP-4i population).  
eNumber of DPP-4i initiators different in both cohorts because for the DPP-4i vs SU comparison, patients could be on any diabetes 
medication (including TZD) except for DPP-4i and SU during the washout period. Similarly for the DPP-4i versus TZD comparison, 
patients could be on any other drugs except DPP-4i and TZD. Further for the DPP-4i versus TZD analysis, patients with prevalent 
diagnosis of heart failure, hypertensive disease with heart failure, chronic kidney disease, edema and use of loop diuretics were 
excluded for all analyses. 
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TABLE 4.4. Risks, risk differences and relative risks for myocardial infarction accounting 
for competing risk by death: DPP-4i versus SU  
  Risk per 100 patients Risk difference (95% CI) Relative risk (95% CI) 
DPP-4i 
   1 year 1.22 (1.13, 1.32) -0.27 (-0.46, -0.06) 0.81 (0.71, 0.95) 
2 year 2.31 (2.15, 2.48) -0.47 (-0.77, -0.15) 0.83 (0.74, 0.93) 
3 year 3.11 (3.07, 3.54) -0.63 (-1.10, -0.21) 0.84 (0.74, 0.94) 
4 year 4.38 (4.04, 4.73) -0.84 (-1.49, -0.22) 0.83 (0.73, 0.95) 
5 year 5.45 (4.97, 6.00) -0.78 (-1.62, 0.12) 0.88 (0.76, 1.02) 
SU 
   1 year 1.49 (1.32, 1.66) Ref Ref 
2 year 2.79 (2.50, 3.04) Ref Ref 
3 year 3.94 (3.56, 4.32) Ref Ref 
4 year 5.26 (4.70, 5.74) Ref Ref 
5 year 6.25 (5.51, 6.96) Ref Ref 
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TABLE 4.5. Risks, risk differences and relative risks for stroke accounting for competing 
risk by death: DPP-4i versus SU  
  Risk per 100 patients Risk difference (95% CI) Relative risk (95% CI) 
DPP-4i 
   1 year 0.92 (0.82, 1.02) -0.11 (-0.23, 0.03) 0.89 (0.79, 1.03) 
2 year 1.72 (1.55, 1.88) -0.26 (-0.44, -0.07) 0.87 (0.78, 0.96) 
3 year 2.46 (2.24, 2.69) -0.30 (-0.58, -0.03) 0.89 (0.79, 0.99) 
4 year 3.16 (2.84, 3.53) -0.49 (-0.87, -0.05) 0.86 (0.76, 0.98) 
5 year 3.63 (3.17, 4.13) -0.81 (-1.30, -0.22) 0.81 (0.71, 0.95) 
SU 
   1 year 1.02 (0.96, 1.10) Ref Ref 
2 year 1.97 (1.86, 2.09) Ref Ref 
3 year 2.76 (2.60, 2.92) Ref Ref 
4 year 3.65 (3.43, 3.88) Ref Ref 
5 year 4.45 (4.14, 4.77) Ref Ref 
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TABLE 4.6. Risks, risk differences and relative risks for myocardial infarction accounting 
for competing risk by death: DPP-4i versus SU Subgroup without prior CVD  
 
Risk per 100 patients Risk difference (95% CI) Relative risk (95% CI) 
DPP-4i 
   1 year 0.64 (0.49, 0.80) -0.10 (-0.26, 0.07) 0.85 (0.67, 1.09) 
2 year 1.42 (1.20, 1.73) -0.04 (-0.30, 0.27) 0.97 (0.80, 1.18) 
3 year 1.79 (1.44, 2.14) -0.41 (-0.83, 0.02) 0.81 (0.64, 1.00) 
4 year 2.36 (1.96, 3.01) -0.49 (-1.31, 0.20) 0.83 (0.65, 1.07) 
5 year 3.49 (2.76, 4.58) 0.08 (-0.91, 1.11) 1.03 (0.75, 1.32) 
SU 
   1 year 0.74 (0.64, 0.83) Ref Ref 
2 year 1.46 (1.33, 1.62) Ref Ref 
3 year 2.22 (2.01, 2.48) Ref Ref 
4 year 2.86 (2.58, 3.19) Ref Ref 
5 year 3.43 (3.03, 3.81) Ref Ref 
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TABLE 4.7. Risks, risk differences and relative risks for stroke accounting for competing 
risk by death: DPP-4i versus SU subgroup without prior CVD 
  Risk per 100 patients Risk difference (95% CI) Relative risk (95% CI) 
DPP-4i 
   1 year 0.48 (0.40, 0.63) -0.21 (-0.34, -0.07) 0.69 (0.54, 0.88) 
2 year 0.92 (0.72, 1.08) -0.48 (-0.77, -0.30) 0.65 (0.48, 0.77) 
3 year 1.36 (1.07, 1.64) -0.76 (-1.19, -0.45) 0.64 (0.49, 0.77) 
4 year 1.66 (1.37, 2.08) -1.19 (-1.70, -0.75) 0.58 (0.46, 0.73) 
5 year 2.17 (1.64, 2.82) -1.39 (-2.10, -0.83) 0.60 (0.45, 0.76) 
SU 
   1 year 0.69 (0.61, 0.78) Ref Ref 
2 year 1.41 (1.26, 1.56) Ref Ref 
3 year 2.11 (1.93, 2.39) Ref Ref 
4 year 2.85 (2.61, 3.24) Ref Ref 
5 year 3.60 (3.25, 4.05) Ref Ref 
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TABLE 4.8. Risks, risk differences and relative risks for myocardial infarction accounting 
for competing risk by death: DPP-4i versus SU Subgroup with prior CVD 
  Risk per 100 patients Risk difference (95% CI) Relative risk (95% CI) 
DPP-4i 
   1 year 1.41 (1.25, 1.54) -0.44 (-0.64, -0.25) 0.76 (0.68, 0.85) 
2 year 2.59 (2.33, 2.84) -0.50 (-0.85, -0.19) 0.83 (0.73, 0.94) 
3 year 3.54 (3.23, 3.91) -0.91 (-1.36, -0.47) 0.79 (0.70, 0.88) 
4 year 4.58 (4.09, 5.08) -0.86 (-1.40, -0.33) 0.84 (0.75, 0.93) 
5 year 6.04 (5.20, 7.06) -0.37 (-1.43, 0.65) 0.94 (0.79, 1.10) 
SU 
   1 year 1.84 (1.72, 1.99) Ref Ref 
2 year 3.11 (2.94, 3.30) Ref Ref 
3 year 4.43 (4.18, 4.70) Ref Ref 
4 year 5.47 (5.17, 5.84) Ref Ref 
5 year 6.53 (6.02, 6.98) Ref Ref 
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TABLE 4.9. Risks, risk differences and relative risks for stroke accounting for competing 
risk by death: DPP-4i versus SU Subgroup with prior CVD 
  Risk per 100 patients Risk difference (95% CI) Relative risk (95% CI) 
DPP-4i 
   1 year 1.18 (1.03, 1.35) -0.05 (-0.25, 0.13) 0.96 (0.81, 1.10) 
2 year 2.19 (1.90, 2.41) -0.14 (-0.47, 0.14) 0.94 (0.81, 1.06) 
3 year 3.08 (2.74, 3.42) -0.12 (-0.56, 0.33) 0.95 (0.83, 1.11) 
4 year 4.01 (3.40, 4.44) -0.23 (-0.81, 0.46) 0.95 (0.81, 1.11) 
5 year 4.30 (3.71, 4.84) -0.74 (-1.48, 0.12) 0.85 (0.71, 1.02) 
SU 
   1 year 1.24 (1.12, 1.35) Ref Ref 
2 year 2.36 (2.14, 2.51) Ref Ref 
3 year 3.20 (2.93, 3.40) Ref Ref 
4 year 4.22 (3.94, 4.55) Ref Ref 
5 year 5.04 (4.58, 5.66) Ref Ref 
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TABLE 4.10. Risks, risk differences and relative risks for myocardial infarction accounting 
for competing risk by death: DPP-4i versus TZD 
  Risk per 100 patients Risk difference (95% CI) Relative risk (95% CI) 
DPP-4i 
   1 year 0.87 (0.76, 1.00) -0.12 (-0.36, 0.09) 0.88 (0.68, 1.12) 
2 year 1.80 (1.61, 2.03) -0.15 (-0.54, 0.22) 0.92 (0.76, 1.12) 
3 year 2.54 (2.24, 2.85) -0.43 (-0.94, 0.16) 0.86 (0.74, 1.06) 
4 year 3.70 (3.19, 4.17) -0.64 (-1.11, 0.33) 0.85 (0.68, 1.09) 
5 year 4.79 (4.25, 5.58) -0.13 (-0.99, 0.70) 0.98 (0.83, 1.31) 
TZD 
   1 year 1.01 (0.82, 1.16) Ref Ref 
2 year 1.97 (1.66, 2.34) Ref Ref 
3 year 2.94 (2.48, 3.36) Ref Ref 
4 year 4.25 (3.56, 4.98) Ref Ref 
5 year 4.85 (4.06, 5.77) Ref Ref 
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TABLE 4.11. Risks, risk differences and relative risks for stroke accounting for competing 
risk by death: DPP-4i versus TZD 
  Risk per 100 patients Risk difference (95% CI) Relative risk (95% CI) 
DPP-4i 
   1 year 0.75 (0.65, 0.85) -0.04 (-0.23, 0.12) 0.94 (0.75, 1.17) 
2 year 1.47 (1.31, 1.71) 0.14 (-0.14, 0.44) 1.10 (0.89, 1.42) 
3 year 2.08 (1.75, 2.42) 0.06 (-0.48, 0.49) 0.97 (0.79, 1.26) 
4 year 2.48 (2.33, 3.31) 0.00 (-0.70, 0.75) 0.99 (0.79, 1.29) 
5 year 3.45 (2.74, 4.16) 0.40 (-0.38, 1.26) 1.13 (0.89, 1.44) 
TZD 
   1 year 0.80 (0.65, 0.93) Ref Ref 
2 year 1.33 (1.06, 1.55) Ref Ref 
3 year 2.10 (1.82, 2.47) Ref Ref 
4 year 2.83 (2.41, 3.35) Ref Ref 
5 year 3.04 (2.57, 3.61) Ref Ref 
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TABLE 4.12. Risks, risk differences and relative risks for myocardial infarction accounting 
for competing risk by death: DPP-4i versus TZD subgroup without prior CVD 
  Risk per 100 patients Risk difference (95% CI) Relative risk (95% CI) 
DPP-4i 
   1 year 0.75 (0.58, 0.89) 0.03 (-0.14, 0.24) 1.04 (0.79, 1.39) 
2 year 1.54 (1.32, 1.81) -0.03 (-0.42, 0.39) 0.98 (0.76, 1.27) 
3 year 1.99 (1.66, 2.33) -0.32 (-0.90, 0.15) 0.86 (0.64, 1.07) 
4 year 2.71 (2.20, 3.33) -0.60 (-1.60, 0.23) 0.82 (0.59, 1.08) 
5 year 3.89 (3.10, 4.93) 0.34 (-1.02, 1.63) 1.09 (0.78, 1.48) 
TZD 
   1 year 0.71 (0.57, 0.86) Ref Ref 
2 year 1.57 (1.29, 1.88) Ref Ref 
3 year 2.29 (1.93, 2.80) Ref Ref 
4 year 3.36 (2.73, 4.04) Ref Ref 
5 year 3.62 (2.76, 4.60) Ref Ref 
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TABLE 4.13. Risks, risk differences and relative risks for stroke accounting for competing 
risk by death: DPP-4i versus TZD subgroup without prior CVD 
  Risk per 100 patients Risk difference (95% CI) Relative risk (95% CI) 
DPP-4i 
   1 year 0.55 (0.44, 0.66) -0.12 (-0.29, 0.05) 0.81 (0.62, 1.09) 
2 year 1.15 (0.92, 1.35) -0.06 (-0.34, 0.22) 0.95 (0.74, 1.22) 
3 year 1.52 (1.22, 1.84) -0.31 (-0.89, 0.09) 0.83 (0.59, 1.06) 
4 year 2.33 (1.89, 2.92) -0.15 (-0.72, 0.61) 0.94 (0.73, 1.30) 
5 year 2.94 (2.23, 3.67) 0.21 (-0.60, 1.25) 1.07 (0.79, 1.54) 
TZD 
   1 year 0.67 (0.53, 0.82) Ref Ref 
2 year 1.21 (0.97, 1.43) Ref Ref 
3 year 1.83 (1.47, 2.23) Ref Ref 
4 year 2.47 (1.98, 3.03) Ref Ref 
5 year 2.74 (2.19, 3.27) Ref Ref 
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TABLE 4.14. Risks, risk differences and relative risks for myocardial infarction accounting 
for competing risk by death: DPP-4i versus TZD subgroup with prior CVD 
  Risk per 100 patients Risk difference (95% CI) Relative risk (95% CI) 
DPP-4i 
   1 year 1.12 (8.56, 1.39) -0.40 (-0.93, -0.01) 0.74 (0.49, 0.99) 
2 year 2.40 (1.85, 2.90) -0.30 (-1.10, 0.36) 0.88 (0.64, 1.51) 
3 year 3.77 (3.00, 4.47) -0.50 (-1.87, 0.74) 0.87 (0.64, 1.20) 
4 year 5.86 (4.54, 7.28) -0.48 (-2.42, 1.67) 0.92 (0.67, 1.29) 
5 year 7.22 (5.72, 9.05) -0.64 (-3.49, 1.88) 0.92 (0.65, 1.32) 
TZD 
   1 year 1.54 (1.18, 1.88) Ref Ref 
2 year 2.71 (2.19, 3.34) Ref Ref 
3 year 4.25 (3.54, 5.36) Ref Ref 
4 year 6.28 (4.78, 7.87) Ref Ref 
5 year 7.74 (5.95, 10.00) Ref Ref 
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TABLE 4.15. Risks, risk differences and relative risks for stroke accounting for competing 
risk by death: DPP-4i versus TZD subgroup with prior CVD 
  Risk per 100 patients Risk difference (95% CI) Relative risk (95% CI) 
DPP-4i 
   1 year 1.15 (0.89, 1.46) 0.00 (-0.44, 0.49) 0.99 (0.68, 1.56) 
2 year 2.15 (1.73, 2.60) 0.59 (-0.10, 1.23) 1.37 (0.95, 2.00) 
3 year 3.28 (2.67, 4.03) 0.47 (-0.49, 1.65) 1.17 (0.86, 1.81) 
4 year 3.82 (3.04, 4.73) 0.19 (-1.09, 1.58) 1.05 (0.75, 1.58) 
5 year 4.35 (3.28, 6.00) 0.70 (-0.79, 2.36) 1.20 (0.82, 1.82) 
TZD 
   1 year 1.17 (0.77, 1.54) Ref Ref 
2 year 1.59 (1.11, 2.06) Ref Ref 
3 year 2.79 (1.90, 3.60) Ref Ref 
4 year 3.67 (2.63, 4.87) Ref Ref 
5 year 3.70 (2.60, 4.90) Ref Ref 
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TABLE 4.16. Adjusted risks and risk differences per 100 patients, and relative risks for 
hospitalization for heart failure after adjusting for competing risk by death : DPP-4i versus 
TZD subgroup without prevalent HF or use of loop diuretics 
  Risk (95% CI) RD (95% CI) RR (95% CI) 
DPP (N = 26,198)   
1 year 0.50 (0.42, 0.61) -0.20 (-0.40, 0.09) 0.67 (0.55, 0.82) 
2 year 1.12 (1.01, 1.30) -0.35 (-0.61, 0.22) 0.77 (0.65, 0.91) 
3 year 1.91 (1.61, 2.34) -0.10 (-0.40, 0.62) 0.84 (0.70, 0.99) 
4 year 3.97 (3.49, 4.47) -0.16 (-0.91, 0.56) 0.96 (0.80, 1.15) 
5 year 4.71 (4.09, 5.37) -0.87 (-2.10, 0.18) 0.84 (0.68, 1.04) 
TZD (N = 18,842) 
 
1 year 0.70 (0.89, 1.19) Ref Ref 
2 year 1.30 (1.72, 2.24) Ref Ref 
3 year 2.03 (2.64, 3.46) Ref Ref 
4 year 4.11 (3.59, 4.71) Ref Ref 
5 year 5.58 (4.70, 6.662) Ref Ref 
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TABLE 4.17. Sensitivity analysis using cardiovascular death as a component of the composite outcome (nonfatal MI, stroke and 
cardiovascular death a) for DPP-4i versus TZD and DPP-4i versus SU 
Comparison Treatment Number 
of new-
users 
events time to event in 
years 
interquartile 
range (median) 
Total 
person-
years 
Incidence 
(per 
100,000 
person 
years) 
Unadjusted HR 
(95% CI) † 
Adjusted HR 
(95%CI) § 
DPP-4i vs SU DPP-4i 44,771 4140 0.58 - 1.96 (1.04) 63,725 6496.67 0.72 (0.69, 0.74) 0.83 (0.81, 0.86) 
  SU 119,436 17783 0.62 - 2.39 (1.21) 197,239 9015.97 1.00 (reference) 1.00 (reference) 
 
DPP-4i vs TZD DPP-4i 26,198 1750 0.58 - 1.96 (1.04) 39,103 4475.36 0.94 (0.87, 1.00) 0.95 (0.88, 1.01) 
  TZD 18,842 1432 0.66 - 2.07 (1.08) 30,237 4735.92 1.00 (reference) 1.00 (reference) 
a Cardiovascular death defined as death after excluding deaths in patients with metastatic cancer during follow-up 
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TABLE 4.18. Sensitivity analysis using Intent to treat approach - number of initiatorsa, events (composite of nonfatal myocardial 
infarction, stroke and death), event rates and crude and adjusted hazard ratios for DPP-4i versus comparators in the entire population as 
well as subgroups based on prior cardiovascular disease 
Comparison Treatment 
Number 
of new-
users 
events 
time to event in 
years 
interquartile 
range (median) 
Total 
person-
years 
Incidence 
(per 
100,000 
person 
years) 
Unadjusted HR 
(95% CI) b 
Adjusted HR 
(95%CI) c 
DPP-4i vs SU DPP-4id 44,771 7358 0.86 - 3.09 (1.82) 95,204 7728.67 0.72 (0.70, 0.74) 0.84 (0.80, 0.85) 
  SU 119,436 29924 0.87 - 3.59 (2.06) 277,496 10783.58 1.00 (reference) 1.00 (reference) 
 
DPP-4i vs TZD DPP-4id 26,198 2762 0.83 - 3.18 (1.82) 56,429 4894.65 0.97 (0.93, 1.03) 0.98 (0.92, 1.03) 
  TZD 18,842 3156 1.79 - 4.58 (3.32) 59,574 5297.61 1.00 (reference) 1.00 (reference) 
DPP-4i - Dipeptidyl peptidase 4 inhibitors, TZD - thiazolidinediones, SU - sulfonylureas, CVD - cardiovascular disease  
a Initiation defined as no dispensed prescriptions for DPP-4i or SU or TZD during the 6 months before initiation and filling a second 
prescription of the same drug/drug class within 6 months after the first prescription.  Under the Intent to treat approach patients not 
censored for treatment changes. 
b Hazard ratios and their 95 % confidence intervals from Cox proportional hazards models for the composite outcome with baseline 
treatment as the only independent covariate.  
c Hazard ratios adjusted for variables in Table 1 and 2 using propensity score weighting (standardized to DPP-4i population).  
d Number of DPP-4i initiators different in both cohorts because for the DPP-4i vs SU comparison, patients could be on any diabetes 
medication (including TZD) except for DPP-4i and SU during the washout period. Similarly for the DPP-4i versus TZD comparison, 
patients could be on any other drugs except DPP-4i and TZD. Further for the DPP-4i versus TZD analysis, patients with prevalent 
diagnosis of heart failure, hypertensive disease with heart failure, chronic kidney disease, edema and use of loop diuretics were 
excluded for all analyses. 
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TABLE 4.19. Study population - DPP-4i versus SU 
  DPP-4i SU 
  N % remaining N % remaining 
Prescription records meeting the 
new-use criteria after 6 months 
washout 
128,327 100.0 195,237 100.0 
Excluding records indicating 
prevalent use of the comparator drug 
during the washout period 
62,715 48.9 173,288 88.8 
Requiring at least 2 scripts of the 
same drug class within 180 days of 
initiation 
51,150 39.9 140,245 71.8 
Excluding records with patient age 
less than 66 years 
47,393 36.9 124,409 63.7 
Excluding records initiating DPP-SU 
dual therapy on the same day 
46,261 36.0 123,235 63.1 
Keeping only 1st record of patients 
meeting the new use criteria more 
than once 
44,771 34.9 119,436 61.2 
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TABLE 4.20. Study population - DPP-4i versus TZD 
  DPP-4i TZD 
  N % remaining N % remaining 
Prescription records meeting the 
new-use criteria after 6 months 
washout 
128,327 100.0 65,561 100.0 
Excluding records indicating 
prevalent use of the comparator drug 
during washout period 
90,003 70.1 56,520 86.2 
Requiring at least 2 scripts of the 
same drug class within 180 days of 
initiation 
72,034 56.1 44,343 67.6 
Excluding records with patient age 
less than 66 years 
67,730 52.8 37,715 57.5 
Excluding records initiating DPP-
TZD dual therapy on the same day 
67,154 52.3 37,113 56.6 
Keeping only 1st record of patients 
meeting the new use criteria more 
than once 
64,632 50.4 36,189 55.2 
Excluding patients with baseline 
diagnosis of heart failure, 
hypertensive disease with heart 
failure, cardiomyopathy, 
arrhythmias/syncope/pacemaker, 
chronic kidney disease, edema and 
use of loop diuretics 
26,198 20.4 18,842 28.7 
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FIGURE 4.1. Weighted cumulative incidence for the composite outcome (non-fatal myocardial 
infarction, stroke and all-cause mortality) 
(A) Dipeptidyl peptidase-4 inhibitors (DPP-4i) versus sulfonylureas (SU) 
(B) Dipeptidyl peptidase-4 inhibitors (DPP-4i) versus thiazolidinediones (TZD)  
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FIGURE 4.2. Weighted cumulative incidence for all-cause mortality (component of composite 
outcome): DPP-4i versus SU 
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FIGURE 4.3. Weighted cumulative incidence for non-fatal myocardial infarction (MI) and stroke: DPP-4i versus SU and DPP-4i 
versus TZD  
DPP-4i - dipeptidyl peptidase-4 inhibitors; SU – sulfonylureas; TZD – thiazolidinediones 
(A) MI - DPP-4i versus SU, (B) Stroke - DPP-4i versus SU, (C) MI – DPP-4i versus TZD, (D) Stroke - DPP-4i versus TZD 
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FIGURE 4.4. Weighted cumulative incidence curves for non-fatal myocardial infarction (MI) and stroke in subgroups based on prior 
CVD: DPP-4i vs SU 
DPP-4i - dipeptidyl peptidase-4 inhibitors; SU – sulfonylureas 
(A) MI - Subgroup with prior CVD; (B) MI – Subgroup without prior CVD;  
(C) Stroke – Subgroup with prior CV; (D) Stroke - Subgroup without prior CVD 
 
 55 
FIGURE 4.5. Weighted cumulative incidence curves for hospitalization for heart failure (HF) 
(A) DPP-4i vs SU; (B) DPP-4i vs TZD 
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FIGURE 4.6. Weighted cumulative incidence curves for non-fatal myocardial infarction (MI) and stroke in subgroups based on prior 
CVD: DPP-4i vs TZD 
DPP-4i - dipeptidyl peptidase-4 inhibitors; TZD - thiazolidinediones 
(A) MI - Subgroup with prior CVD; (B) MI – Subgroup without prior CVD;  
(C) Stroke – Subgroup with prior CV; (D) Stroke - Subgroup without prior CVD 
 
 57 
CHAPTER 5. CALENDAR TIME AS AN INSTRUMENTAL VARIABLE IN 
ASSESSING THE RISK OF HEART FAILURE WITH ANTIHYPERGLYCEMIC 
DRUGS 
I. Introduction 
The prevalence of diabetes continues to increase around the world. In the United States 
about 9.3% of the adult population had diabetes in 2012.61 The use of antihyperglycemic drugs 
has increased over the past few years and accounts for about 12% of the cost of diabetes.13, 62  
The antihyperglycemic drug market has seen introduction of several new drugs in the last decade 
– the most notable being an amylin analog, glucagon-like peptide-1 receptor agonists, dipeptidyl 
peptidase-4 inhibitors (DPP-4i) and sodium glucose transport protein-2 inhibitors. Along with 
introduction of new drugs, the last decade also saw emerging safety concerns about 
thiazolidinediones, an established class of antihyperglycemic drugs. In 2007, a meta-analysis 
raised concerns over the cardiovascular safety of rosiglitazone 63 after which it was pulled from 
the European market 46  and in September 2010 the Food and Drug Administration (FDA) 
announced that its use would be restricted in the US.64 In 2010 the FDA also released a drug 
safety communication that it was evaluating data from an epidemiologic study examining 
whether pioglitazone increased the risk of bladder cancer.65 In 2011 the FDA approved updates 
to the labelling pioglitazone products to include “an increased risk of bladder cancer in 
pioglitazone users.”66 
 According to a recent analysis 13 of the IMS health data examining the market trends of 
antihyperglycemic drugs, the newly approved drugs, particularly the DPP-4i class quickly gained 
significant market share and was the most commonly prescribed new drug class by 2012.  On the 
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other hand, the use of thiazolidinediones decreased by 2012 with the use of pioglitazone reaching 
only half its peak use in 2008 and negligible use of rosiglitazone.  
In observational studies, the use of an active comparator greatly reduces the potential for 
confounding by indication and results in treatment cohorts that are comparable with respect to 
measured and unmeasured confounders. 67  DPP-4i and TZD are both generally used as second-
line antihyperglycemic treatment, with intermediate (DPP-4i) to high (TZD) efficacy, low risk of 
hypoglycemia 14 and comparable costs before the generic form of pioglitazone was introduced in 
August 2012.15 The DPP-4i and TZD drugs are therefore expected to be in therapeutic equipoise 
in a population excluding anyone with clear contraindications. This was demonstrated in our 
previous work comparing DPP-4i and TZD in a population of patients without heart failure and 
related conditions 68 where the measured baseline characteristics were well-balanced among 
initiators of DPP-4i and TZD which increases the confidence that unmeasured confounders were 
also well-balanced by design, although this cannot be proven. The increase in the use of DPP-4i 
with a simultaneous decrease in TZD use over a short period of time also provides an 
opportunity to use calendar time as an instrumental variable (IV) as suggested previously in other 
settings.16 
 While IV methods are generally indicated in studies where substantial unmeasured 
confounding is expected28, 69, 70  (likely in cases where an active comparator does not exist), 
according to our knowledge, this is a unique setting where there exists both an active comparator 
and also a potential IV driven by the antihyperglycemic drug market which enables a direct 
comparison of the two methods and their estimators. Using hospitalization for heart failure (HF) 
as a positive control outcome (TZDs are known to increase the risk of HF whereas DPP-4i drugs 
sitagliptin and alogliptin do not) 3, 4, 71 we explored the use of calendar time as an IV and 
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compared this approach to an active comparator new-user study comparing DPP-4i versus TZD 
(actual treatment received) in sample of Medicare beneficiaries without a history of HF or related 
conditions. 
II. Methods 
Study Population 
We used a 20% random sample of Medicare beneficiaries >65 years with fee-for-service 
Part A (hospital coverage), B (outpatient care) and D (dispensed prescription drugs) enrollment 
in at least one month during a calendar year from January 1, 2007 (2006 for Part A and B) to 
December 31, 2013.  This dataset contains information about demographics, enrollment, 
diagnoses, procedures and prescription drugs for each enrollee.49, 50 
From this population, we identified new-users of DPP-4i or TZD. Prevalent users of 
DPP-4i or TZD in the 6 months before initiation were excluded, but patients were allowed to be 
on other antihyperglycemic treatments during the washout period. Initiation was defined as the 
first prescription of the drug with the index date defined as the date of dispensing. Since TZDs 
are contraindicated in patients with existing heart failure 33.54  (which can lead to intractable 
confounding by contraindication if not properly accounted for), we further excluded patients 
with diagnoses of heart failure, hypertensive disease with heart failure and closely related 
conditions of cardiomyopathy, arrhythmias, chronic kidney disease, edema and use of loop 
diuretics. Patients needed to have at least 6 months of continuous Part D enrollment and at least 
12 months parts A and B enrollment pre-index. To ensure that patients were actually started on 
the drugs, we restricted our cohorts to patients with a second prescription for the same drug class 
dispensed within 6 months after the index date.  
 
 60 
Instrumental variable (IV) 
An IV is an observed variable associated with the variation in exposure like randomized 
assignment in a clinical trial.28 To be valid, an IV should be: 1) associated with the treatment, 2) 
unrelated to patient characteristics and 3) related to the outcome only through its association with 
the treatment (exclusion restriction). Additionally, in order to estimate the average treatment 
effect in the ‘compliers’ an additional assumption of ‘monotonicity’ (no ‘defiers’) should hold. 
Monotonicity requires that the instrument affects the treatment deterministically in one 
direction.28  
We defined the IV as a binary variable (post versus pre-period) anchored around the time 
of the crossover of the drug initiation curves (June – September 2010) which was also the time 
when the FDA issued communications about restriction of rosiglitazone and concerns about the 
safety of pioglitazone (September 2010). In our study, ‘compliers’ are patients whose initial 
treatment is determined by the calendar time in which they initiated treatment – i.e, TZD if 
initiating before the crossover of the drug initiation curves and DPP-4i if initiating after the 
crossover. We identified an ‘optimal’ IV by evaluating the percentage of compliers, i.e, the 
strength of the instrument’s effect on the received treatment.16 We examined the instrument in 
relation to IV assumptions using measured covariates, falsification tests and expert knowledge. 
The binary measure of calendar time was decided before examining the effect estimates. 
Outcome 
The outcome used in this study was hospitalization for HF defined using International 
Classification of Diseases, Ninth Revision (ICD-9) code 428.xx in the primary position in 
inpatient claims. This definition has a specificity >98% but a very low sensitivity of 21% in a 
Medicare population.32 TZDs are known to be associated with an increased risk of heart failure 
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34 ,71 and while saxagliptin is suspected to be associated with an increased risk of heart failure, 
recently reported placebo-controlled trials indicate no increased incidence of HF with DPP-4i 
drugs sitagliptin and alogliptin (which is >80% of our cohort).2, 3, 35  HF hospitalization is 
therefore a positive control outcome in our study enabling the comparison of performance of the 
propensity score weighting method comparing the actual treatments initiated and IV analysis 
comparing levels of the calendar time instrument. Patients were followed up from the second fill 
date till the earliest of the following – outcome (HF hospitalization), death, end of enrollment or 
2 years after the index date.  
Confounding control and analysis 
We used weighted Kaplan Meier methods to estimate the 1- and 2-year risk difference 
(RD) for HF hospitalization under the two analytic approaches, i.e, comparing the actual 
treatment initiated (DPP-4i vs TZD) and levels of the calendar time IV (‘post’ versus ‘pre’ 
periods). Under the ‘treatment received’ approach, propensity scores (PS) were used to control 
for measured confounding. Using variables listed in table 1 measured before initiation, we 
predicted the probability for initiating DPP-4i versus TZD for each patient (the PS) 36 using a 
logistic regression model without including the year of initiation in the model as it can increase 
the variability of effect estimates and can increase bias in case of unmeasured confounding if it 
acts as an instrument.40, 41, 36 We then assigned a weight of 1/PS to DPP-4i and a weight of (1/(1-
PS)) to TZD and stabilized both groups by marginal prevalence of the treatment actually 
received. 42 Such inverse probability of treatment (IPTW) weighting creates a pseudo-population 
in which the association between covariates and treatment is removed by the weighting described 
above. Under the assumption of no unmeasured confounding this method allows us to contrast 
two scenarios: “what would have happened if the entire population initiated DPP-4i’ versus 
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‘“what would have happened if the entire population initiated TZD’.42 Using IPTW weighted 
Kaplan Meier curves we then estimated the RDs for HF hospitalization using treatment as the 
strata variable.  
The effect of the IV levels on HF hospitalization was observed by the IV estimates of RD 
scaled by the strength of the instrument to estimate the average treatment effect among the 
‘compliers’. Next we generated covariate-adjusted IV estimates of the RD using weighted 
Kaplan-Meier methods analogous to the IPTW weighted method outlined above and scaled this 
by the strength of the instrument. Under this approach, we first predicted the probability (PP) of 
the instrument as a function of baseline covariates and assigned a weight of 1/PP to the ‘post’ 
period and 1/(1-PP) to the ‘pre’ period and stabilized the weights by the marginal prevalence of 
the instrument. 
These methods are appreciably different and results apply to different patient populations 
(IV estimates apply to the marginal patients while IPTW methods apply to the whole population). 
Propensity score models used the full study population and we performed sensitivity analyses in 
the reduced instrumental variable cohort to evaluate selection differences that may have been 
introduced based on instrumental variable exclusions. 16 Next we performed a sensitivity analysis 
restricting the study cohort to patients who initiated DPP-4i or TZD between July 2007 and 
December 2011, with follow-up allowed through December 2013. This approach excluded 
anyone who initiated therapy during or after January 2012, who would not have the potential for 
a 2-year follow-up before the end of the study (and therefore potentially violate the assumption 
of ‘non-informative’ censoring i.e., the assumption that patients who drop out of the study should 
do so for reasons unrelated to HF).43 Finally, we performed additional analyses with different 
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definitions of the instrument (IV defined using a cut-point and by comparing periods with 
maximum separation).   
III. Results 
As seen in FIGURE 5.1, calendar time greatly affected treatment initiation. The ‘optimal’ 
binary IV compared the periods from October 2010 through December 2013 (hereafter referred 
to as ‘post’; N = 22,696) with the period from January 2008 to May 2010 (‘pre’; N = 20,283). 
This definition excludes patients in the region where the curves intersect (June 2010 through 
September 2010) which was the time around which the drug initiation curves were close together 
and also when the FDA issued drug safety communications about TZDs. With this IV definition, 
the DPP-4i treatment rates were 78% and 38% in the post and pre periods and the strength of the 
IV was 40%.  
TABLE 5.1 presents the baseline covariates comparing the actual treatment initiated 
(DPP-4i versus TZD) and the levels of the IV (post versus pre). While the measured covariates 
are well balanced by design across the treatment received (DPP-4i versus TZD), the balance was 
slightly better across the levels of the IV as illustrated by the average standardized absolute mean 
difference (average SAMD, 4.5 vs 3.0%). This indicates that the instrument is independent of the 
measured risk factors of the outcome and potentially also unmeasured covariates. The IV 
particularly improved the balance for race, diabetes complications and health seeking behaviors 
like statin use, influenza vaccinations, and lipid panels. For example, the SAMD for lipid panels 
comparing DPP-4i versus TZD was 11.8% which reduced to 5.8% across the levels of the IV. 
TABLE 5.2 shows the number of initiators, events, median time on treatment and 
incidence rates for HF hospitalization across levels of the IV and treatment initiated. In the full 
population comparing DPP-4i versus TZD, the crude incidence rate per 100,000 was 563 in 
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DPP-4i and 676 in TZD initiators. The 1- and 2-year risks for HF hospitalization were 0.5% and 
1.2% for DPP-4i and 0.7% and 1.3% for TZD respectively (FIGURE 5.2). In the reduced IV 
population, crude incidence rate per 100,000 person-years was 509 in the post period and 695 in 
the pre period. The 1- and 2-year risks for HF hospitalization were 0.4% and 1.1% in the post 
period and 0.7% and 1.4% in the pre period respectively. 
FIGURE 5.3 shows the 1- and 2-year RDs per 100 patients for HF hospitalization 
obtained using different analyses (TABLE 5.3). The crude RD was not very different from the 
IPTW weighted RD obtained by comparing DPP-4i versus TZD (expected because of the 
relative balance of baseline covariates by design). The IV estimates of the RDs scaled by the 
strength of the instrument were consistent overall with the IPTW weighted RDs indicating a 
protective effect with the DPP-4i but relatively less precise and farther from the null. The 2-year 
RD per 100 patients obtained using the IV analysis scaled by IV strength was -0.62 (-0.99, -0.25) 
indicating that of the 1000 compliant patients treated with DPP-4i, 6 additional patients had no 
HF hospitalization till 1 year compared with those treated with TZD. Covariate adjusted IV 
estimates of the RD were virtually similar (FIGURE 5.3) (TABLE 5.3). 
Sensitivity analyses in a population restricted to patients initiating on or before December 
2011, analyses using IPTW weighting in the reduced IV population (TABLE 5.4) and analyses 
using different definitions of the instrumental variable yielded similar results (FIGURE 5.4, 
FIGURE 5.5). 
IV. Discussion and Conclusions 
In this study we compared the performance of two analytic methods - IPTW weighting 
comparing DPP-4i versus TZD initiators and the IV analysis comparing initiators of either DPP-
4i or TZD during later years with initiators of these drug classes in earlier years in assessing the 
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risk of HF hospitalization, a positive control outcome, in DPP-4i versus TZD initiators. In a 
population of patients without evidence of prior HF or related conditions, DPP-4i and TZD, both 
second-line antihyperglycemic drugs are in therapeutic equipoise and measured patient 
characteristics were well balanced across the two cohorts as seen in table 1. This also indicates 
lesser chance of unmeasured confounding, although this cannot be ruled out completely. While 
IV methods are generally employed in cases where substantial unmeasured confounding is 
expected, according to our knowledge, this is a unique situation where both methods were 
expected to be equally valid and this was confirmed by our results. Both approaches indicated a 
decreased risk of HF hospitalization with DPP-4i relative to TZD, an effect that was consistent 
across a number of sensitivity analyses.  
The absolute 1-year risks of HF hospitalization reported in the randomized trials on 
sitagliptin (>80% of our DPP-4i cohort) and pioglitazone (>90% of our TZD cohort) are 
approximately 1% and 2% respectively.4, 71 These trials compared sitagliptin and pioglitazone 
with placebo and found no increased risk with sitagliptin and 0.5% increased risk with 
pioglitazone relative to placebo at 1 year, but there are no data about RDs comparing DPP-4i and 
TZD. In our study, the ICD-9 code based definition of HF had a high specificity, but a low 
sensitivity of 21%32 which led to an underestimation of absolute HF risks and therefore RDs with 
both the IPTW and IV methods. While we could have chosen to estimate relative risks (expected 
to be unbiased because of near-perfect specificity of the HF definition), IV methods used to 
derive relative measures require additional strong assumptions about the homogeneity of risks 
within the levels of the treatment and measured covariates.28, 72  These assumptions are often 
implicit in IV methods based on structural equation regression models that yield estimates of 
absolute measure of effect (RD) and this is what we used in this study.28, 72 
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While the RDs obtained using both analytic approaches generally agreed, the IV 
estimates had wider confidence intervals as expected and the magnitudes of the RDs differed 
because the two analytic methods apply to potentially different populations and are based on 
different assumptions. The IPTW weighted RD is the average treatment effect in the entire 
population indicated for treatment. However, the scaled RD from the IV analysis is the average 
treatment effect in the 40% compliers from the reduced IV population. Scaling of the IV estimate 
of the RD involves dividing the effect of the instrument on the outcome (measured as risk 
difference) by the IV strength (rates of DPP-4i treatment in the post minus pre periods). The 
weaker the instrument, the larger the scaled estimate gets relative to the unscaled RD, potentially 
multiplying any biases present in the unscaled RD.28 In a sensitivity analysis we defined the 
instrument by a cut-point (before and after July 2010) which made this a weaker instrument 
(difference in DPP-4i treatment rates post – pre = 25%), and the scaled 1-year RD was -0.73 (-
1.74, 0.27) which is higher in magnitude compared to the RD estimate scaled with a stronger 
instrument in the main analysis, but in the same direction. In another sensitivity analysis we 
compared the periods with maximum separation (December 2011 – December 2012 versus June 
2008 – June 2009). This definition of the IV led to the IV strength of 50% (stronger than the 
main analysis) and as expected the scaled 1-year RD was closer to the unscaled estimate (-0.45, 
CI:-0.92, 0.05). Thus, scaling could explain some of the differences in magnitude of the IV 
estimates of RDs compared to the IPTW weighed RDs seen in the main analysis. We compared 
the characteristics of the compliers with that of the full population and found that while the 
populations were generally similar, the compliers were slightly less likely to be on other 
antidiabetic drugs like metformin and sulfonylureas, but the difference was not big enough to 
explain our results (TABLE 5.5). 
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It is also possible that instrumental variable assumptions are violated. While we were able 
to empirically observe that the instrument strongly affected the treatment initiation between 2008 
and 2013 (assumption 1), the assumption of calendar time being unrelated to the outcome 
through other mechanisms may be violated. A recent study reports a decline in the rates of HF 
hospitalizations from 1999 to 2011 among Medicare beneficiaries with and without a history of 
heart failure73 which could be due to several reasons including increases in the use of statins, 
decreased smoking and increasing outpatient management of HF. The Hospital Readmissions 
Reduction Program (HRRP) started in late 2012 requires CMS to penalize hospitals with excess 
readmissions for certain conditions including HF, which could be somewhat responsible to the 
decreasing trend in HF hospitalizations, but this is not expected to affect earlier years of the data 
used for this study.74 To minimize the effect of time trends, we conducted a sensitivity analysis 
using a dichotomous cut-point of calendar time (described above) and estimated 1-year RD 
comparing the 12 months after versus before the cut-point but the results pointed in the same 
direction, although the magnitude was different. The assumption of IV being unrelated to patient 
characteristics is also not empirically verifiable, but it is upheld by the improvement in the 
covariate balance across the levels of the IV compared to the balance across the levels of the 
treatment initiated. The assumption of ‘no defiers’ also seems to be reasonable in this study as it 
is unlikely that a patient would initiate DPP-4i before June 2010 – September 2010 (region of 
crossover of the curves) while an identical patient would initiate TZD in the ‘post’ period in spite 
of the warnings about adverse effects associated with TZD. The generic form of pioglitazone 
was available starting August 2012, but this would potentially affect the last year of our study 
and not the earlier years. Given the difference in efficacy of DPP-4i versus TZD (intermediate 
versus high), it is possible that patients with high HbA1C initiated TZD in the post period, but 
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based on expert knowledge that is not expected to be a significant concern. There were no events 
that would preclude DPP-4i initiator in the ‘pre’ period from receiving DPP-4i in the ‘post’ 
period, especially given the positive reports about the lack of serious adverse events with these 
agents in the past few years.6, 35, 51 
Some additional caveats should be considered. First, ‘scaling by strength of the 
instrument’ may have implications for bias amplification due to covariate imbalances across the 
levels of the instrument. While we compared the covariate balance achieved across the 
‘treatments initiated’ to the balance across the levels of the IV as commonly recommended28 , 
this approach misses a key component (the scaling factor) of the relative bias comparing IV and 
non-IV approaches.75  As proposed by Jackson, we calculated the bias component for the two 
analytic approaches - the prevalence difference for the treatments received and the prevalence 
difference multiplied by the scaling factor (1/0.40) for the IV levels (TABLE 5.6).75  With this 
approach the differences across the IV levels somewhat increased for variables like younger age 
groups, statins and baseline use of sulfonylureas, indicating that not adjusting for these variables 
could bias our results. However our adjusted and unadjusted IV estimates are only slightly 
different indicating no significant concern for confounding by these variables in our main 
analysis. However, weak instruments (i.e., scaling factor closer to 0) can lead to greater 
imbalance across the levels of the IV and not adjusting for these variables might lead to bias. 
Second, our first-treatment carried forward / intent-to-treat (ITT) analysis approach could lead to 
exposure misclassification as it does not take into account treatment changes. However, the IV 
estimator is a measure of the association between the treatment assignment (i.e., treatment 
intention) and the outcome. Therefore, using a conceptually uniform ITT approach for the IPTW 
analysis comparing DPP-4i versus TZD initiation would facilitate direct comparison of the RDs 
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obtained by the two methods. Third, death is a competing event in the older population and not 
accounting for competing risks could theoretically overestimate the risk of HF. However, 
analyses with and without accounting for competing risks were virtually similar in a previous 
study using the same population indicating that competing risk by death is not a serious concern 
for this study. 68 Fourth, our use of the term compliance/compliers refers to prescriber behaviors 
rather than patient behaviors as in an RCT. Finally, it could be argued that unmeasured 
confounding exists in the DPP-4i versus TZD comparison by unmeasured factors like body mass 
index (BMI) or smoking. However, we used chronic obstructive pulmonary disease (COPD) as a 
proxy for smoking in our PS models and previously found using data from the Medicare Current 
Beneficiary Survey that BMI is not likely to affect the choice of initiation of DPP-4i versus TZD 
in these patients which reduces the concern of confounding by these variables.60 
Strengths of our study included the ability to identify a strong instrument of calendar time 
driven by the dynamics of the antihyperglycemic drug market over a short period of time. This 
created a setting for a ‘natural experiment’ that creates an allocation of exposure similar to that 
of a randomized experiment. Use of an active comparator created a setting of treatment equipoise 
between DPP-4i and TZD as described before. It is often conservatively suggested to avoid IV 
methods when the assumptions are likely to be violated because relatively minor violations of the 
assumptions may lead to large biases69, which can particularly be a problem when there is no 
valid comparison analytic method. However, in our setting, the IV and IPTW methods address 
different biases and are based on different assumptions some of which cannot be directly 
quantified; but the use of a positive control outcome and observing consistent results with either 
method implies that both methods may be equally valid, or supplement each other at the very 
least. In summary the use of calendar time as an IV in settings where real-world market 
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dynamics lead to profound changes in preferred treatments is worth consideration as previously 
suggested in other settings.16 
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V. Tables and Figures 
TABLE 5.1. Characteristics of patients by treatment initiated and levels of the instrumental 
variable 
  By levels of the instrument BY actual treatment initiated 
Post (N 
= 22,696) 
Oct 2010 
to Dec 
2013 
Pre (N = 
20,283) 
Jan 2008 
to May 
2010 
SAMD DPP-4i   
(N = 
26,198) 
TZD    
(N = 
18,842) 
SAMD 
  % % % % % % 
TZD 22.5 62.4     
DPP-4i 77.5 37.6     
Patient demographics 
66 to 75 years old 66.2 64.2 4.2 64.8 65.7 2.0 
76 to 85 years old 27.6 29.6 4.3 28.9 28.3 1.1 
86 years and above 6.1 6.2 0.3 6.4 5.9 1.8 
Male 41.4 41.3 0.2 39.7 43.6 8.0 
White 73.7 74.0 0.7 75.5 71.4 9.4 
Black 9.2 9.9 2.3 8.9 10.5 5.3 
Other 17.1 16.1 2.7 15.6 18.2 6.8 
Baseline comorbidities 
Diagnosis of acute 
myocardial infarction 
0.8 0.7 1.5 0.8 0.5 3.9 
Diagnosis of old 
myocardial infarction 
2.2 1.8 2.9 2.2 1.6 4.5 
Angina 3.2 3.0 1.2 3.5 2.6 5.3 
Diagnosis of Stroke or 
TIA 
4.8 3.9 4.5 4.7 4.0 3.2 
Other acute and 
subacute forms of 
ischemic heart disease 
1.4 1.2 1.7 1.6 1.0 4.6 
Obesity diagnosis 0.9 0.8 1.0 1.0 0.6 3.8 
Diabetic nephropathy 3.0 2.8 1.3 3.0 2.8 0.8 
Diabetic neuropathy 15.2 12.8 7.1 15.3 12.7 7.4 
Diabetic retinopathy 14.4 12.4 5.9 13.8 12.9 2.7 
Bone fractures 4.4 3.6 3.8 4.1 3.9 0.6 
Chronic obstructive 
pulmonary disease 
11.2 10.2 3.2 11.0 10.4 1.9 
Cancer (Non-Skin) 14.9 13.0 5.6 15.1 12.4 7.8 
Dementia 4.9 4.7 0.9 4.9 4.6 1.2 
Foot ulcers 7.1 5.9 4.9 7.0 5.8 4.7 
Inflammatory GI 
diseases 
0.7 0.6 0.7 0.7 0.7 0.2 
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Liver disease 5.3 4.3 4.4 5.2 4.3 4.5 
Pancreatitis 0.8 0.7 0.8 0.8 0.7 0.5 
Alcoholism 0.1 0.1 0.6 0.1 0.1 0.6 
Aortic aneurysm 1.5 1.3 1.6 1.6 1.2 3.1 
Baseline medication use 
Metformin 71.3 73.3 4.3 73.9 70.5 7.4 
Sulfonylureas 51.2 54.4 6.4 52.0 54.1 4.2 
Glucagon-like peptide-
1 agonists 
1.7 1.8 0.4 1.8 1.6 1.2 
Long acting insulin 11.9 10.9 3.0 11.3 11.5 0.8 
Short acting insulin 4.3 4.2 0.5 4.1 4.4 1.2 
Statins 70.2 65.5 10.1 70.2 64.7 11.8 
Angiotensin 
converting enzyme 
inhibitors 
39.7 40.1 0.8 38.5 41.9 6.9 
Angiotensin receptor 
blockers 
16.6 15.6 2.5 17.3 14.4 7.8 
Beta blockers 34.9 35.1 0.4 36.7 32.4 9.0 
Calcium channel 
blockers 
27.1 25.3 4.1 27.1 25.2 4.3 
Other diuretics 39.3 40.8 2.9 40.5 39.4 2.2 
Health Care utilization 
Blood tests 8.5 9.4 3.2 9.2 8.6 2.3 
Influenza vaccinations 55.9 52.0 7.8 56.2 51.0 10.4 
Lipid panels 88.5 86.5 5.9 89.2 85.3 11.8 
Mammogram 23.0 23.6 1.3 24.9 21.1 9.0 
Average SAMD     3.0     4.5 
Instrumental variable definition anchored around the time of the FDA drug safety 
communications about thiazolidinediones and the crossing of the drug initiation curves. This 
definition excludes patients in the region where the curves intersect (June 2010 through 
September 2010) where the curves were close together (N = 2061, 4.5% of the total 
population of 45,040).    
DPP-4i - Dipeptidyl peptidase 4 inhibitors, TZD - thiazolidinediones, SAMD: standardized 
absolute mean difference.  
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TABLE 5.2. Number of new-users, heart failure hospitalizations, time on treatment, total 
person time and incidence for comparisons of levels of the instrument and treatment 
initiated  
Comparison Level 
Number 
of new-
users 
events 
Duration of 
follow-up* in 
years 
interquartile 
range (median) 
Total 
person-
years* 
Incidence 
(per 
100,000 
person 
years) 
Post vs Pre^ Post 22,696 146 0.64 - 2.00 (1.36) 28,661 509.40 
  Pre 20,283 255 2.00 - 2.00 (2.00) 36,682 695.16 
  
DPP-4i vs 
TZD 
DPP-4i 26,198 210 1.79 - 2.00 (2.00) 37,252 563.73 
  TZD 18,841 215 1.68 - 2.00 (2.00) 31,791 676.29 
DPP-4i - Dipeptidyl peptidase 4 inhibitors, TZD - thiazolidinediones 
^Post - Oct 2010 to Dec 2013, Pre - Jan 2008 to May 2010 
*Under the first treatment carried forward/intent-to-treat analysis patients were followed up 
from the second prescription of the initiated drug to earliest of the outcome occurrence, 
death or 2-years after initiation without accounting for treatment changes during follow-up 
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TABLE 5.3. Risk differences using instrumental variable and propensity score weighted 
approaches in the main analysis 
  1-year Risk difference 2-year Risk difference 
  RD LCL UCL RD LCL UCL 
        
Unadjusted -0.2 -0.34 -0.02 -0.17 -0.34 0.02 
IV estimator unscaled -0.24 -0.39 -0.10 -0.35 -0.58 -0.10 
IV estimator scaled by IV strength 
of 40% 
-0.62 -0.99 -0.25 -0.88 -1.46 -0.25 
Adjusted IV estimator scaled by IV 
strength of 40% 
-0.58 -1.00 -0.19 -0.76 -1.39 -0.12 
PS IPTW weighted -0.20 -0.33 -0.05 -0.18 -0.30 -0.03 
PS - Propensity score, IPTW - Inverse probability of treatment weights, IV - Instrumental 
variable, RD - risk difference. LCL and UCL - lower and upper limits of the 95% confidence 
intervals respectively 
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TABLE 5.4. Risk differences with sensitivity analyses 
  1-year Risk difference 2-year Risk difference 
  RD LCL UCL RD LCL UCL 
Sensitivity analysis: IPTW weighted risk difference for DPP-4i vs TZD in the reduced IV 
population (N = ) 
PS IPTW weighted in reduced IV 
population 
-0.19 -0.26 0.02 -0.16 -0.32 0.15 
Sensitivity analysis: IV analysis in a population where patients without potential for a 2 year 
follow-up, i.e. patients initiating therapy during or after January 2012 were excluded (N = 
29,724: post = 9,442, pre = 20,282, IV strength 30%) 
IV estimator scaled by IV strength 
modified population 
-0.76 -1.37 -0.11 -1.06 -1.93 0.15 
PS: Propensity score, IPTW - Inverse probability of treatment weights, IV - Instrumental 
variable 
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TABLE 5.5. Comparison of characteristics of compliers with full population 
  Full population 
(N=45,040) 
IV strength 
in subgroup 
(%) 
Ratio of IV 
strength = IV 
strength in 
subgroup/IV 
strength 
overall 
% of 
patients in 
subgroup = 
# in 
subgroup/IV 
population 
Prevalence 
of subgroup 
in compliers 
= ratio of IV 
strength*% 
of patients 
in subgroup 
Percent 
difference 
Compliers 
versus full 
population 
  % %  %   
        
66 to 75 years old 65.19 39.87 1.00 65.29 65.41 0 
76 to 85 years old 28.64 39.7 1.00 28.55 28.48 0 
86 years and above 6.17 42.67 1.07 6.16 6.60 0 
Male 41.31 39.82 1.00 41.34 41.36 0 
White 73.76 38.71 0.97 73.82 71.79 2 
Black 9.58 43.65 1.10 9.53 10.45 1 
Other 16.66 43.16 1.08 16.65 18.06 1 
Diagnosis of acute 
myocardial infarction 
0.71 44.06 1.11 0.72 0.80 0 
Diagnosis of old 
myocardial infarction 
1.96 34.24 0.86 1.98 1.71 0 
Angina 3.13 37.25 0.94 3.11 2.91 0 
Diagnosis of Stroke or 
TIA 
4.38 40.96 1.03 4.39 4.51 0 
Other acute and 
subacute forms of 
ischemic heart disease 
1.33 39.1 0.98 1.34 1.32 0 
Obesity diagnosis 0.83 30.18 0.76 0.83 0.63 0 
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Diabetic nephropathy 2.90 37.41 0.94 2.91 2.73 0 
Diabetic neuropathy 14.19 35.98 0.90 14.07 12.72 1 
Diabetic retinopathy 13.46 39.72 1.00 13.42 13.39 0 
Bone fractures 4.00 40.58 1.02 4.00 4.08 0 
Chronic obstructive 
pulmonary disease 
10.76 41.48 1.04 10.74 11.20 0 
Cancer (Non-Skin) 14.00 39.58 0.99 13.98 13.90 0 
Chronic lung diseases 10.57 39.24 0.99 10.57 10.42 0 
Dementia 4.77 40.54 1.02 4.78 4.87 0 
Depression 10.97 41.55 1.04 10.96 11.45 0 
Foot ulcers 6.48 40.8 1.03 6.50 6.66 0 
Inflammatory GI 
diseases 
0.65 34.03 0.86 0.66 0.56 0 
Liver disease 4.82 36.89 0.93 4.82 4.47 0 
Other renal disorders 2.03 39.92 1.00 2.03 2.04 0 
Pancreatitis 0.73 31.2 0.78 0.74 0.58 0 
Peripheral vascular 
disease (claudication) 
9.01 38.43 0.97 8.95 8.64 0 
Proteinuria 2.12 38.05 0.96 2.13 2.03 0 
Urinary tract 
infection/cystitis 
17.41 42.95 1.08 17.39 18.77 1 
Alcoholism 0.10 33.64 0.85 0.10 0.08 0 
Aortic aneurysm 1.45 35.24 0.89 1.44 1.28 0 
Metformin 72.47 38.75 0.97 72.26 70.35 2 
Sulfonylureas 52.89 38.06 0.96 52.70 50.40 2 
Glucagon-like peptide-1 
agonists 
1.72 20.92 0.53 1.73 0.91 1 
Long acting insulin 11.39 39.49 0.99 11.41 11.32 0 
Short acting insulin 4.22 42.65 1.07 4.22 4.52 0 
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Anticholinergic drugs 1.51 37.12 0.93 1.50 1.40 0 
Statins 67.85 40 1.01 67.94 68.28 0 
Angiotensin converting 
enzyme inhibitors 
39.95 40.72 1.02 39.88 40.80 1 
Angiotensin receptor 
blockers 
16.06 37.94 0.95 16.13 15.37 1 
Beta blockers 34.93 37.4 0.94 35.00 32.89 2 
Calcium channel 
blockers 
26.27 39.15 0.98 26.27 25.84 0 
Other diuretics 40.04 38.82 0.98 40.00 39.02 1 
Blood tests 8.93 38.73 0.97 8.88 8.64 0 
Influenza vaccinations 53.99 38.25 0.96 54.04 51.93 2 
Lipid panels 87.60 39.54 0.99 87.54 86.97 1 
Mammogram 23.29 38.44 0.97 23.26 22.46 1 
Pap Smear 6.65 37.23 0.94 6.62 6.19 0 
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TABLE 5.6. Bias components based on covariate imbalances calculated for the 'treatment received' and 'instrumental 
variable' approaches 
  
By levels of the instrument BY actual treatment initiated 
Post (N = 
22,696) Oct 
2010 to Dec 
2013 
Pre (N = 
20,283) Jan 
2008 to May 
2010 
Prevalence 
difference*1/
0.40 
DPP-4i   (N 
= 26,198) 
TZD    (N = 
18,842) 
Prevalence 
difference 
  % % % % % % 
TZD 22.5 62.4 
    
DPP-4i 77.5 37.6 
    
Patient demographics 
66 to 75 years old 66.2 64.2 5 64.8 65.7 -0.9 
76 to 85 years old 27.6 29.6 -5 28.9 28.3 0.6 
86 years and above 6.1 6.2 -0.25 6.4 5.9 0.5 
male 41.4 41.3 0.25 39.7 43.6 -3.9 
white 73.7 74 -0.75 75.5 71.4 4.1 
black 9.2 9.9 -1.75 8.9 10.5 -1.6 
other 17.1 16.1 2.5 15.6 18.2 -2.6 
Baseline comorbidities 
Diagnosis of acute 
myocardial infarction 
0.8 0.7 0.25 0.8 0.5 0.3 
Diagnosis of old 
myocardial infarction 
2.2 1.8 1 2.2 1.6 0.6 
Angina 3.2 3 0.5 3.5 2.6 0.9 
Diagnosis of Stroke or 
TIA 
4.8 3.9 2.25 4.7 4 0.7 
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Other acute and 
subacute forms of 
ischemic heart disease 
1.4 1.2 0.5 1.6 1 0.6 
Obesity diagnosis 0.9 0.8 0.25 1 0.6 0.4 
Diabetic nephropathy 3 2.8 0.5 3 2.8 0.2 
Diabetic neuropathy 15.2 12.8 6 15.3 12.7 2.6 
Diabetic retinopathy 14.4 12.4 5 13.8 12.9 0.9 
Bone fractures 4.4 3.6 2 4.1 3.9 0.2 
Chronic obstructive 
pulmonary disease 
11.2 10.2 2.5 11 10.4 0.6 
Cancer (Non-Skin) 14.9 13 4.75 15.1 12.4 2.7 
Dementia 4.9 4.7 0.5 4.9 4.6 0.3 
Foot ulcers 7.1 5.9 3 7 5.8 1.2 
Inflammatory GI 
diseases 
0.7 0.6 0.25 0.7 0.7 0 
Liver disease 5.3 4.3 2.5 5.2 4.3 0.9 
Pancreatitis 0.8 0.7 0.25 0.8 0.7 0.1 
Alcoholism 0.1 0.1 0 0.1 0.1 0 
Aortic aneurysm 1.5 1.3 0.5 1.6 1.2 0.4 
Baseline medication use 
Metformin 71.3 73.3 -5 73.9 70.5 3.4 
Sulfonylureas 51.2 54.4 -8 52 54.1 -2.1 
Glucagon-like peptide-1 
agonists 
1.7 1.8 -0.25 1.8 1.6 0.2 
Long acting insulin 11.9 10.9 2.5 11.3 11.5 -0.2 
Short acting insulin 4.3 4.2 0.25 4.1 4.4 -0.3 
Statins 70.2 65.5 11.75 70.2 64.7 5.5 
Angiotensin converting 
enzyme inhibitors 
39.7 40.1 -1 38.5 41.9 -3.4 
  
8
1
 
Angiotensin receptor 
blockers 
16.6 15.6 2.5 17.3 14.4 2.9 
Beta blockers 34.9 35.1 -0.5 36.7 32.4 4.3 
Calcium channel 
blockers 
27.1 25.3 4.5 27.1 25.2 1.9 
Other diuretics 39.3 40.8 -3.75 40.5 39.4 1.1 
Health Care utilization 
Blood tests 8.5 9.4 -2.25 9.2 8.6 0.6 
Influenza vaccinations 55.9 52 9.75 56.2 51 5.2 
Lipid panels 88.5 86.5 5 89.2 85.3 3.9 
Mammogram 23 23.6 -1.5 24.9 21.1 3.8 
Instrumental variable definition anchored around the time of the FDA drug safety communications about 
thiazolidinediones and the crossing of the drug initiation curves. This definition excludes patients in the region where the 
curves intersect (June 2010 through September 2010) where the curves were close together (N = 2061, 4.5% of the total 
population of 45,040).    
DPP-4i - Dipeptidyl peptidase 4 inhibitors, TZD - thiazolidinediones 
Calculation of bias component based on the method by Jackson et. al. 
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FIGURE 5.1. Initiation of dipeptidyl peptidase 4 inhibitors (DPP-4i) versus thiazolidinediones (TZD) across calendar time 
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FIGURE 5.2. Probability of being event-free 
(A) By treatment initiated (N = 45,040) and  
(B) By levels of the calendar time instrument (N = 42,979). Patient assignment to instrumental 
variable category is based on month and year treatment was initiated. Oct 2010 to Dec 2013 
(post) versus Jan 2008 to May 2010 (pre) 
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FIGURE 5.3. Comparison of risk differences for heart failure hospitalization. Estimates of RD 
are based on risks per 100 patients taken from Kaplan–Meier survival curves. The instrumental 
variable estimator is scaled by a compliance percentage of 40%. Adjusted estimates account for 
the variables presented in Table 1. IPTW = inverse probability of treatment weight. 
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FIGURE 5.4. Sensitivity analyses comparing 1-year periods with maximum separation: December 2011 – December 2012 versus June 
2008 – June 2009 
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FIGURE 5.5. Sensitivity analyses comparing 1-year periods using cut-point definition of the instrumental variable: August 2010 – 
August 2011 versus July 2009 – July 2010  
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CHAPTER 6. CONCLUSIONS AND PUBLIC HEALTH SIGNIFICANCE 
I. Summary of specific aims 
Diabetes prevalence has been growing worldwide and over a quarter of the U.S. adults 
65+ years of age have diabetes.44  Cardiovascular disease is the leading cause of morbidity and 
mortality in these patients and the risk increases with age.45  The use of antihyperglycemic drugs 
has been increased tremendously in the past few years accounting for approximately 12% of the 
total cost of diabetes.62  The antihyperglycemic drug market has typically been very dynamic 
with a number of new agents being added in the last decade and more drug safety and 
effectiveness data is becoming available about the existing therapies. Cardiovascular safety of 
antihyperglycemic drugs is a question of great interest and regulatory agencies require a 
thorough assessment of cardiovascular risk in the antihyperglycemic drug development 
programs.47 
In this study, dipeptidyl peptidase-4 inhibitors (DPP-4i) is the main drug class of interest. 
DPP-4i were first introduced in the U.S. in 2006 and are currently indicated as second line 
treatment of diabetes along with other oral drugs sulfonylureas (SU), thiazolidinediones (TZD) 
and sodium-glucose co-transporter 2 inhibitors (introduced in 2013). DPP-4i have intermediate 
efficacy, low risk of hypoglycemia and are weight neutral which is a desirable feature of 
antihyperglycemic drugs. In this study we focused on the cardiovascular effects of DPP-4i 
relative to therapeutic alternatives in older adults and examined some substantive and 
methodological aims as described below.
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II. Summary of Aim 1 
Randomized placebo-controlled clinical trials have examined the CV effects of dipeptidyl 
peptidase-4 inhibitors (DPP-4i), but there are limited data on the comparative incidence relative 
to therapeutic alternatives, including sulfonylureas (SU) and thiazolidinediones (TZD).2-4 The 
existing observational studies report no increased relative risk of myocardial infarction (MI) and 
stroke with DPP-4i, but the evidence on heart failure (HF) is mixed.7-12,25  All the studies mainly 
reported summary relative risk measures but not the absolute risk measures which may be 
important to put the issue in context. Further, several studies used a combined pool of non-DPP-
4i drugs as the comparator making interpretation of the results difficult and less useful for 
physicians for making treatment decisions. Ours is the first epidemiologic study comparing the 
incidence of CV events with DPP-4i versus clinically relevant active comparators in a US 
population of older adults with a high prevalence of comorbidity and long duration of diabetes 
(both of which could affect the effects of DPP-4i on CV risk).  
We found that there was no increased risk of MI, stroke and HF hospitalizations with 
DPP-4i relative to SU or TZD in this population of older adults. Since TZDs are associated with 
an increased risk of HF, we used HF as a positive control outcome in this study expecting no 
increased risk with DPP-4i and that is what we observed. Our results were robust to a number of 
sensitivity and subgroup analyses. The risk of the composite outcome (MI, stroke and all-cause 
mortality) seemed lower with DPP-4i then SU, but this was mainly due to death rather than MI 
or stroke for which the risk differences were small throughout the study. 
Our study had several strengths including use of active-comparator new user cohort 
design which avoids biases related to prevalent user designs, synchronizes follow-up and 
minimizes imbalance of baseline covariates as the drugs being compared are for the same 
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indication.27, 67  We used well defined comparators (SU and TZD in separate analyses) unlike few 
other observational studies that compared DPP-4i to a pooled group of comparators thus making 
interpretation of results difficult. Use of propensity score weighting further balanced the baseline 
covariates thereby minimizing confounding by these variables. Limitations of our study included 
a short treatment duration (which is mostly due to real-world drug use patterns), low sensitivity 
of the ICD-9 codes used to define HF, inability to capture cardiovascular death as cause specific 
death information is not present in the Medicare claims (but we used all-cause mortality as a 
proxy since this is responsible for more than half of the deaths in diabetic patients). Finally we 
could not adjust for smoking and BMI which can affect CV risk. However, we previously found 
that smoking and BMI do not meaningfully affect the choice of initiation of DPP-4i versus 
comparators thereby reducing concerns about unmeasured confounding by these variables.60 
  In summary, we did not observe an increased short-term risk of MI, stroke, mortality or 
HF hospitalization with DPP-4i versus relevant oral second line diabetes drugs in a population of 
older adults. Along with the RCT results, our results based on real world drug use and effects are 
relevant to physicians for making antihyperglycemic treatment choices.   
III. Summary of Aim 2 
A recent study 13  examining the market trends of antihyperglycemic drugs reported that 
newly approved drugs, particularly the DPP-4i class quickly gained significant market share and 
was the most commonly prescribed new drug class by 2012.  On the other hand, the use of TZD 
decreased by 2012 potentially due to the safety concerns associated with this class in the last 
decade. DPP-4i and TZD are both second-line antihyperglycemic drugs, with intermediate (DPP-
4i) to high (TZD) efficacy, low risk of hypoglycemia 14  and comparable costs before the generic 
form of pioglitazone was introduced in August 2012.15 The DPP-4i and TZD drugs are therefore 
 90 
expected to be in therapeutic equipoise in a population excluding anyone with clear 
contraindications as demonstrated in aim 1. The increase in the use of DPP-4i with a 
simultaneous decrease in TZD use over a short period of time also provides an opportunity to use 
calendar time as an instrumental variable (IV) as suggested previously in other settings.16 Using 
hospitalization for heart failure (HF) as a positive control outcome we explored the use of 
calendar time as an IV and compared this approach to an active comparator new-user study 
comparing DPP-4i versus TZD (actual treatment received) in sample of Medicare beneficiaries 
without a history of HF or related conditions. 
We found that calendar time greatly affected the initiation of DPP-4i and TZD and the 
two curves crossed in 2010 around the time when the Food and Drug Administration (FDA) 
issued drug safety communications about TZDs. In our study the IV compared the periods from 
October 2010 through December 2013 (‘post’) with the period from January 2008 to May 2010 
(‘pre’) leading to IV strength of 40%. Covariate balance across the levels of the IV was slightly 
better than the covariate balance achieved across the treatments initiated. The IV estimates of the 
risk difference were similar in direction to the RDs obtained using the propensity score 
weighting methods, both indicating lesser risk of HF hospitalizations with DPP-4i as expected. 
The magnitude of the RDs obtained using the two methods were somewhat different which could 
be because the two analytic approaches are based on different populations and assumptions. 
Results were consistent across a number of sensitivity analyses.  
Strengths of our study included ability to identify a strong instrument of calendar time 
driven by the dynamics of the antihyperglycemic drug market over a short period of time, thus 
creating a setting for a ‘natural experiment’. Use of an active comparator created a setting of 
treatment equipoise between DPP-4i and TZD as described before. One of the limitations of our 
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study included potential violation of one of the IV assumptions which requires that time is not 
related to the outcome through pathways other than the treatment. However there have been 
reports about a decreasing trend in HF hospitalizations which could violate this assumption.73 We 
conducted a sensitivity analyses to minimize the effect of time trends, but the results were 
virtually similar. Secondly while the assumption is monotonicity (‘no defiers’) is expected to 
hold in our study, it is possible that it is violated in the later periods when the generic form of 
pioglitazone was introduced in 2012 when patients could initiate TZD in the ‘post’ period. 
While IV methods are generally indicated in settings where substantial unmeasured 
confounding is expected, according to our knowledge ours is a unique setting where both IV and 
‘treatment received approaches’ may be equally valid. These two approaches address different 
biases and are based on different assumptions some of which cannot be directly quantified; but 
the use of a positive control outcome and observing consistent results with either method implies 
that both methods may supplement each other at the very least. In summary the use of calendar 
time as an IV in settings where real-world market dynamics lead to profound changes in 
preferred treatments is worth consideration. 
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